

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 02 CA/CAPLUS enhanced with pre-1907 records from Chemisches
Zentralblatt
NEWS 3 OCT 19 BEILSTEIN updated with new compounds
NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 5 NOV 19 WPIX enhanced with XML display format
NEWS 6 NOV 30 ICSD reloaded with enhancements
NEWS 7 DEC 04 LINPADOCDB now available on STN
NEWS 8 DEC 14 BEILSTEIN pricing structure to change
NEWS 9 DEC 17 USPATOLD added to additional database clusters
NEWS 10 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 11 DEC 17 DGENE now includes more than 10 million sequences
NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in
MEDLINE segment
NEWS 13 DEC 17 MEDLINE and LMEMLINE updated with 2008 MeSH vocabulary
NEWS 14 DEC 17 CA/CAPLUS enhanced with new custom IPC display formats
NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content
from USPATOLD
NEWS 16 JAN 02 STN pricing information for 2008 now available
NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 19 JAN 28 MARPAT searching enhanced
NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22 JAN 28 MEDLINE and LMEMLINE reloaded with enhancements
NEWS 23 FEB 08 STN Express, Version 8.3, now available
NEWS 24 FEB 20 PCI now available as a replacement to DPCI
NEWS 25 FEB 25 IFIREF reloaded with enhancements
NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:52:25 ON 02 MAR 2008

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'USPATFULL' ENTERED AT 18:52:52 ON 02 MAR 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 18:52:52 ON 02 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:52:52 ON 02 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (multi-layer?)
L1 140563 (MULTI-LAYER?)

=> s (ppi layer or proton pump inhibit? layer)
L2 2 (PPI LAYER OR PROTON PUMP INHIBIT? LAYER)

=> d 1-2

L2 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2004:215056 USPATFULL
TI Novel pharmaceutical formulation containing a proton pump inhibitor and
an antacid
IN Niecestro, Robert, Pocono Pines, PA, UNITED STATES
Kositprapa, Unchalee, Davie, FL, UNITED STATES
Oh, Yoon, Pembroke Pines, FL, UNITED STATES
Nangia, Avinash, Weston, FL, UNITED STATES
Cardinal, John R., Tamarac, FL, UNITED STATES
Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI US 2004166162 A1 20040826
AI US 2004-761805 A1 20040121 (10)
PRAI US 2003-442337P 20030124 (60)
DT Utility
FS APPLICATION
LN.CNT 1055
INCL INCLM: 424/472.000
INCLS: 514/339.000
NCL NCLM: 424/472.000
NCLS: 514/339.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
[ICS,7]
IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 2004:7871 USPATFULL
TI Transmucosal delivery of proton pump inhibitors
IN Widder, Kenneth, Rancho Santa Fe, CA, UNITED STATES
Hall, Warren, San Diego, CA, UNITED STATES
Olmstead, Kay, San Diego, CA, UNITED STATES
PI US 2004006111 A1 20040108
AI US 2003-353143 A1 20030127 (10)
PRAI US 2002-351909P 20020125 (60)
US 2002-374761P 20020422 (60)
DT Utility
FS APPLICATION
LN.CNT 1161
INCL INCLM: 514/338.000
INCLS: 424/471.000
NCL NCLM: 514/338.000
NCLS: 424/471.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
[ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-24 [I,C*];
A61K0009-24 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61K0033-06 [I,C*]; A61K0033-10 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> (proton pump inhibit? gran/)
(PROTON IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> (proton pump inhibit? gran?)
(PROTON IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (proton pump inhibit? gran?)
L3 4 (PROTON PUMP INHIBIT? GRAN?)

=> d 1-4

L3 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:277813 USPATFULL
TI Oral dosage forms including an antiplatelet agent and an acid inhibitor
IN Goldsmith, Mark A., Menlo Park, CA, UNITED STATES
Vadas, Elizabeth, Dorval, CANADA
PA Cogentus Pharmaceuticals, Inc, Menlo Park, CA, UNITED STATES (U.S.
corporation)
PI US 2007243243 A1 20071018
AI US 2007-696554 A1 20070404 (11)
PRAI US 2006-789543P 20060404 (60)
US 2006-812326P 20060609 (60)
DT Utility
FS APPLICATION
LN.CNT 3072
INCL INCLM: 424/451.000
INCLS: 514/165.000; 514/301.000; 514/338.000; 424/464.000
NCL NCLM: 424/451.000
NCLS: 424/464.000; 514/165.000; 514/301.000; 514/338.000
IC IPCI A61K0031-616 [I,A]; A61K0031-60 [I,C*]; A61K0031-4743 [I,A];
A61K0031-4738 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*];
A61K0009-48 [I,A]; A61K0009-20 [I,A]
IPCR A61K0031-60 [I,C]; A61K0031-616 [I,A]; A61K0009-20 [I,C];
A61K0009-20 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A];
A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4738 [I,C];
A61K0031-4743 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2007:176725 USPATFULL
TI Oral pharmaceutical formulations containing non-steroidal
anti-inflammatory drugs and acid inhibitors
IN Tananbaum, James B., Palo Alto, CA, UNITED STATES
Vadas, Elizabeth, Dorval, CANADA
PA Cogentus Pharmaceuticals, Inc., Menlo Park, CA, UNITED STATES (U.S.
corporation)
PI US 2007154542 A1 20070705
AI US 2006-640107 A1 20061215 (11)
PRAI US 2005-755131P 20051230 (60)
DT Utility
FS APPLICATION
LN.CNT 832
INCL INCLM: 424/457.000
INCLS: 514/226.200
NCL NCLM: 424/457.000
NCLS: 514/226.200
IC IPCI A61K0031-5415 [I,A]; A61K0009-52 [I,A]
IPCR A61K0031-5415 [I,C]; A61K0031-5415 [I,A]; A61K0009-52 [I,C];
A61K0009-52 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2006:240140 USPATFULL
TI Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
IN Hall, Warren, Del Mar, CA, UNITED STATES
Olmstead, Kay, San Diego, CA, UNITED STATES
Weston, Laura, Escondido, CA, UNITED STATES
PA Santarus, Inc. (U.S. corporation)
PI US 2006204585 A1 20060914
AI US 2006-338608 A1 20060124 (11)
RLI Continuation-in-part of Ser. No. US 2004-893203, filed on 16 Jul 2004, PENDING
PRAI US 2003-488321P 20030718 (60)
DT Utility
FS APPLICATION
LN.CNT 4308
INCL INCLM: 424/489.000
INCLS: 514/338.000; 424/717.000; 424/715.000
NCL NCLM: 424/489.000
NCLS: 424/715.000; 424/717.000; 514/338.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-14 [I,A]; A61K0033-00 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-46 [I,C*]; A61K0009-46 [I,A]; A61K0033-00 [I,C]; A61K0033-00 [I,A]; A61K0033-06 [I,C*]; A61K0033-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 4 USPATFULL on STN

Full Text

AN 2004:215056 USPATFULL
TI Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
IN Niecestro, Robert, Pocono Pines, PA, UNITED STATES
Kositprapa, Unchalee, Davie, FL, UNITED STATES
Oh, Yoon, Pembroke Pines, FL, UNITED STATES
Nangia, Avinash, Weston, FL, UNITED STATES
Cardinal, John R., Tamarac, FL, UNITED STATES
Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI US 2004166162 A1 20040826
AI US 2004-761805 A1 20040121 (10)
PRAI US 2003-442337P 20030124 (60)
DT Utility
FS APPLICATION
LN.CNT 1055
INCL INCLM: 424/472.000
INCLS: 514/339.000
NCL NCLM: 424/472.000
NCLS: 514/339.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24 [ICS,7]
IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (omperazole or lansoprazole or pantoprazole or pariprazole or leminoprazole)
L4 1960 (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR LEMINOPRAZOLE)

=> s (proton pump inhibit?)
L5 2032 (PROTON PUMP INHIBIT?)

=> s 14 or 15
L6 2992 L4 OR L5

=> s (layer? and gran?)
L7 272277 (LAYER? AND GRAN?)

=> s 16 and 17
L8 1474 L6 AND L7

=> s (antacid layer?)
L9 6 (ANTACID LAYER?)

=> s 18 and 19
L10 2 L8 AND L9

=> d 1-2

L10 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2005:323970 USPATFULL
TI Solid dosage form for acid-labile active ingredient
IN Li, Shun-Por, Lansdale, PA, UNITED STATES
Wynn, David, Huntingdon Valley, PA, UNITED STATES
Sowden, Harry S., Glenside, PA, UNITED STATES
PI US 2005281876 A1 20051222
AI US 2004-871851 A1 20040618 (10)
DT Utility
FS APPLICATION
LN.CNT 1501
INCL INCLM: 424/473.000
NCL NCLM: 424/473.000
IC [7]
ICM A61K009-24
ICS A61K009-36
IPCI A61K0009-24 [ICM,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
IPCR A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-20 [I,C*];
A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-30 [I,C*];
A61K0009-36 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 2004:215056 USPATFULL
TI Novel pharmaceutical formulation containing a **proton pump inhibitor** and an antacid
IN Niecestro, Robert, Pocono Pines, PA, UNITED STATES
Kositprapa, Unchalee, Davie, FL, UNITED STATES
Oh, Yoon, Pembroke Pines, FL, UNITED STATES
Nangia, Avinash, Weston, FL, UNITED STATES
Cardinal, John R., Tamarac, FL, UNITED STATES
Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
PI US 2004166162 A1 20040826
AI US 2004-761805 A1 20040121 (10)
PRAI US 2003-442337P 20030124 (60)
DT Utility
FS APPLICATION
LN.CNT 1055
INCL INCLM: 424/472.000
INCLS: 514/339.000
NCL NCLM: 424/472.000
NCLS: 514/339.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24 [ICS,7]
IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:52:25 ON 02 MAR 2008)

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:52:52 ON 02 MAR 2008

```

L1      140563 S (MULTI-LAYER?)
L2      2 S (PPI LAYER OR PROTON PUMP INHIBIT? LAYER)
L3      4 S (PROTON PUMP INHIBIT? GRAN?)
L4      1960 S (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR
L5      2032 S (PROTON PUMP INHIBIT?)
L6      2992 S L4 OR L5
L7      272277 S (LAYER? AND GRAN?)
L8      1474 S L6 AND L7
L9      6 S (ANTACID LAYER?)
L10     2 S L8 AND L9

=> s (omperazole or lansoprazole or pantoprazole or pariprazole or leminoprazole)/clm
L11     499 (OMPERAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR PARIPRAZOLE OR
        LEMINOPRAZOLE)/CLM

=> s (proton pump inhibit?)/clm
L12     484 (PROTON PUMP INHIBIT?)/CLM

=> s l11 or l12
L13     737 L11 OR L12

=> s (layer? and gran?)/clm
L14     10742 (LAYER? AND GRAN?)/CLM

=> s l13 and l14
L15     58 L13 AND L14

=> d 1-58

L15 ANSWER 1 OF 58  USPATFULL on STN
Full Text
AN      2008:22877  USPATFULL
TI      Solid Dosage Form Comprising Proton Pump Inhibitor and Suspension Made
        Thereof
IN      Persson, Eva, Lund, SWEDEN
        Trofast, Eva, Lund, SWEDEN
PA      ASTRAZENECA AB, Sodertalje, SWEDEN, SE-151 85 (non-U.S. corporation)
PI      US 2008020053      A1  20080124
AI      US 2005-722387      A1  20051220 (11)
        WO 2005-SE1972      20051220
        20070621  PCT 371 date
PRAI    US 2004-638435P      20041222 (60)
DT      Utility
FS      APPLICATION
LN.CNT  1033
INCL    INCLM: 424/490.000
        INCLS: 514/303.000; 514/338.000; 514/777.000
NCL     NCLM: 424/490.000
        NCLS: 514/303.000; 514/338.000; 514/777.000
IC      IPCI  A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4427 [I,C*];
        A61K0047-36 [I,A]; A61K0009-14 [I,A]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 58  USPATFULL on STN
Full Text
AN      2007:224389  USPATFULL
TI      Stable oral formulation containing benzimidazole derivative
IN      Vanderbist, Francis, Beersel, BELGIUM
        Sereno, Antonio, Melsbroek, BELGIUM
        Baudier, Philippe, Uccle, BELGIUM
        Deboeck, Arthur, Gurabo, PR, UNITED STATES
PI      US 2007196486      A1  20070823
AI      US 2007-790054      A1  20070423 (11)
RLI     Continuation of Ser. No. US 2003-399482, filed on 18 Apr 2003, ABANDONED
PRAI    WO 2000-BE126      20001020
        WO 2001-BE184      20011018
DT      Utility
FS      APPLICATION
LN.CNT  585
INCL    INCLM: 424/472.000
        INCLS: 514/338.000
NCL     NCLM: 424/472.000

```

NCLS: 514/338.000
IC IPCI A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
IPCR A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0031-4427 [I,C];
A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 58 USPATFULL on STN

Full Text

AN 2007:217184 USPATFULL
TI Delayed release pharmaceutical oral dosage form and method of making
same
IN Zerbe, Horst G., Hudson, CANADA
Ispas-Szabo, Pompilia, Greenfield Park, CANADA
PA Intelgenx Corp., Saint-Laurent, CANADA (non-U.S. corporation)
PI US 2007190139 A1 20070816
AI US 2006-403262 A1 20060413 (11)
PRAI US 2006-772547P 20060213 (60)
DT Utility
FS APPLICATION
LN.CNT 1491
INCL INCLM: 424/468.000
INCLS: 514/573.000
NCL NCLM: 424/468.000
NCLS: 514/573.000
IC IPCI A61K0009-22 [I,A]; A61K0031-557 [I,A]
IPCR A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61K0031-557 [I,C];
A61K0031-557 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 58 USPATFULL on STN

Full Text

AN 2007:191199 USPATFULL
TI Taste masked compositions of erythromycin a and derivatives thereof
IN Dabre, Rahul, Magpur, INDIA
Nagaprasad, Vishnubhotla, Hyderabad, INDIA
Malik, Rajiv, Vienna, AUSTRIA
PI US 2007167380 A1 20070719
AI US 2003-509824 A1 20030403 (10)
WO 2003-IB1221 20030403
20050622 PCT 371 date
PRAI IN 2002-4262002 20020403
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 514/029.000
INCLS: 514/054.000
NCL NCLM: 514/029.000
NCLS: 514/054.000
IC IPCI A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-734 [I,A]
IPCR A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0009-16 [I,C*];
A61K0009-16 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
A61K0031-429 [I,C*]; A61K0031-43 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]; A61K0031-734 [I,C]; A61K0031-734 [I,A];
A61K0038-55 [I,C*]; A61K0038-55 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 58 USPATFULL on STN

Full Text

AN 2007:190191 USPATFULL
TI Proton pump-inhibitor-containing capsules which comprise subunits
differently structured for a delayed release of the active ingredient
IN Odidi, Isa, Toronto, CANADA
Odidi, Amina, Toronto, CANADA
PI US 2007166370 A1 20070719
AI US 2004-561700 A1 20040603 (10)
WO 2004-CA825 20040603
20061110 PCT 371 date
PRAI US 2003-482439P 20030626 (60)
US 2004-548903P 20040302 (60)
DT Utility
FS APPLICATION
LN.CNT 1285

INCL INCLM: 424/451.000
 INCLS: 424/457.000; 514/338.000
 NCL NCLM: 424/451.000
 NCLS: 424/457.000; 514/338.000
 IC IPCI A61K0009-48 [I,A]; A61K0009-52 [I,A]; A61K0031-4439 [I,A];
 A61K0031-4427 [I,C*]
 IPCR A61K0009-48 [I,C]; A61K0009-48 [I,A]; A61K0009-16 [N,C*];
 A61K0009-16 [N,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
 A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-50 [I,C*];
 A61K0009-50 [I,A]; A61K0009-52 [I,C]; A61K0009-52 [I,A];
 A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-44 [I,C*];
 A61K0031-44 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 58 USPATFULL on STN

Full Text

AN 2007:161584 USPATFULL
 TI Stable capsule preparation
 IN Nagahara, Naoki, Osaka-shi, JAPAN
 Ito, Hiroki, Suita-shi, JAPAN
 Nonomura, Muneo, Osaka-shi, JAPAN
 PI US 2007141137 A1 20070621
 AI US 2005-591164 A1 20050303 (10)
 WO 2005-JP3621 20050303
 20060830 PCT 371 date
 PRAI JP 2004-60613 20040304
 DT Utility
 FS APPLICATION
 LN.CNT 1890
 INCL INCLM: 424/451.000
 INCLS: 514/338.000
 NCL NCLM: 424/451.000
 NCLS: 514/338.000
 IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-48 [I,A]
 IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-48 [I,C];
 A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-58 [I,A];
 A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-34 [I,C*];
 A61K0047-34 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A];
 A61P0001-00 [I,C*]; A61P0001-04 [I,A]; C07D0401-00 [N,C*];
 C07D0401-12 [N,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A];
 A61K0047-42 [I,C*]; A61K0047-42 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 58 USPATFULL on STN

Full Text

AN 2007:55439 USPATFULL
 TI Stable drug form for oral administration with benzimidazole derivatives
 as active ingredient and process for the preparation thereof
 IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
 Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
 Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
 Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
 Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
 Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
 PI US 2007048380 A1 20070301
 US 7276253 B2 20071002
 AI US 2006-502830 A1 20060811 (11)
 RLI Division of Ser. No. US 2003-665081, filed on 16 Sep 2003, ABANDONED
 Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, GRANTED,
 Pat. No. US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23
 Dec 1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27
 Jun 1997, UNKNOWN
 PRAI DE 1996-19626045 19960628
 DT Utility
 FS APPLICATION
 LN.CNT 967
 INCL INCLM: 424/472.000
 INCLS: 514/338.000
 NCL NCLM: 424/472.000
 NCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000;

424/490.000; 424/494.000; 514/338.000
 IC IPCI A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
 IPCI-2 A61K0009-14 [I,A]; A61K0009-16 [I,A]; A61K0009-20 [I,A];
 A61K0009-24 [I,A]; A61K0009-28 [I,A]
 IPCR A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-16 [I,C];
 A61K0009-16 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,A];
 A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-28 [I,C];
 A61K0009-28 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 58 USPATFULL on STN

Full Text

AN 2007:48221 USPATFULL
 TI Pellet formulations of acid-labile benzimidazonle compounds
 IN Martin, Luis Carvajal, Madrid, SPAIN
 Asensio, Juan Carlos Asensio, Zaragoza, SPAIN
 Tirado, Francisco Javier Sevilla, Zaragoza, SPAIN
 PI US 2007042043 A1 20070222
 AI US 2004-554727 A1 20040427 (10)
 WO 2004-EP50618 20040427
 20051028 PCT 371 date
 PRAI ES 2003-976 20030429
 DT Utility
 FS APPLICATION
 LN.CNT 515
 INCL INCLM: 424/470.000
 INCLS: 514/338.000; 424/489.000
 NCL NCLM: 424/470.000
 NCLS: 424/489.000; 514/338.000
 IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-26 [I,A];
 A61K0009-14 [I,A]
 IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-14 [I,C];
 A61K0009-14 [I,A]; A61K0009-26 [I,C]; A61K0009-26 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 58 USPATFULL on STN

Full Text

AN 2007:35958 USPATFULL
 TI Gastric acid secretion inhibiting composition
 IN Pettersson, Anders, Lilla Edet, SWEDEN
 Nystrom, Christer, Uppsala, SWEDEN
 Hakansson, Yvonne, Uppsala, SWEDEN
 PA OREXO AB, UPPSALA, SWEDEN (non-U.S. corporation)
 PI US 2007031497 A1 20070208
 AI US 2006-544750 A1 20061010 (11)
 RLI Continuation of Ser. No. US 2005-531598, filed on 25 Nov 2005, PENDING A
 371 of International Ser. No. WO 2003-SE1598, filed on 15 Oct 2003
 PRAI SE 2002-3065 20021016
 DT Utility
 FS APPLICATION
 LN.CNT 1345
 INCL INCLM: 424/473.000
 INCLS: 514/338.000
 NCL NCLM: 424/473.000
 NCLS: 514/338.000
 IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
 IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-00 [I,C*];
 A61K0009-00 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A];
 A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C];
 A61K0009-24 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-341 [I,C*];
 A61K0031-341 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A];
 A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0045-00 [I,C*];
 A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 10 OF 58 USPATFULL on STN

Full Text

AN 2006:301112 USPATFULL
 TI Compositions and methods for inhibiting gastric acid secretion

IN Kostadinov, Aleksey, Rehovot, ISRAEL
David, Ayelet, Negev, ISRAEL
Glozman, Sabina, Rehovot, ISRAEL
PI US 2006257467 A1 20061116
AI US 2005-191688 A1 20050727 (11)
PRAI US 2005-679664P 20050511 (60)
DT Utility
FS APPLICATION
LN.CNT 983
INCL INCLM: 424/451.000
INCLS: 514/338.000; 514/557.000; 514/574.000; 424/464.000; 424/466.000;
424/468.000
NCL NCLM: 424/451.000
NCLS: 424/464.000; 424/466.000; 424/468.000; 514/338.000; 514/557.000;
514/574.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-19 [I,A];
A61K0031-185 [I,C*]; A61K0009-48 [I,A]; A61K0009-20 [I,A];
A61K0009-46 [I,A]; A61K0009-22 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-20 [I,C];
A61K0009-20 [I,A]; A61K0009-22 [I,C]; A61K0009-22 [I,A];
A61K0009-46 [I,C]; A61K0009-46 [I,A]; A61K0009-48 [I,C];
A61K0009-48 [I,A]; A61K0031-185 [I,C]; A61K0031-19 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 58 USPATFULL on STN

Full Text

AN 2006:195039 USPATFULL
TI Spheroids, preparation method thereof and pharmaceutical compositions
IN Chenevier, Philippe, 5656 rue Woudbury, Montreal, QC, CANADA H3T 1F7
Marechal, Dominique, Laval, CANADA
PA Ethypharm, Houdan, FRANCE, F-78550 (non-U.S. corporation)
PI US 2006165794 A1 20060727
AI US 2003-530052 A1 20031003 (10)
WO 2003-FR2909 20031003
20050804 PCT 371 date
PRAI FR 2002-12333 20021004
DT Utility
FS APPLICATION
LN.CNT 744
INCL INCLM: 424/472.000
NCL NCLM: 424/472.000
IC IPCI A61K0009-24 [I,A]
IPCR A61K0009-24 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C];
A61K0009-50 [I,C*]; A61K0009-50 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 12 OF 58 USPATFULL on STN

Full Text

AN 2006:188327 USPATFULL
TI Stable pharmaceutical composition comprising an active substance in the
form of solid solution
IN Stanic Ljubin, Tijana, Ljubljana, SLOVENIA
Sirca, Judita, Ljubljana, SLOVENIA
PI US 2006159762 A1 20060720
AI US 2005-317769 A1 20051223 (11)
PRAI SI 2004-200400351 20041224
DT Utility
FS APPLICATION
LN.CNT 768
INCL INCLM: 424/472.000
INCLS: 514/338.000
NCL NCLM: 424/472.000
NCLS: 514/338.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-24 [I,C];
A61K0009-24 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 13 OF 58 USPATFULL on STN

Full Text

AN 2006:188325 USPATFULL

TI Drug composition having active ingredient adhered at high concentration
 to spherical core
 IN Yoneyama, Shuji, Osaka-shi, JAPAN
 Bando, Hiroto, Osaka-shi, JAPAN
 PA Aoyama & Partners (non-U.S. corporation)
 PI US 2006159760 A1 20060720
 AI US 2004-548504 A1 20040310 (10)
 WO 2004-JP3075 20040310
 20050909 PCT 371 date
 PRAI JP 2003-66344 20030312
 DT Utility
 FS APPLICATION
 LN.CNT 6689
 INCL INCLM: 424/472.000
 INCLS: 514/338.000
 NCL NCLM: 424/472.000
 NCLS: 514/338.000
 IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
 IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-16 [I,C*];
 A61K0009-16 [I,A]; A61K0009-22 [I,C*]; A61K0009-22 [I,A];
 A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-30 [I,C*];
 A61K0009-32 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
 A61K0009-52 [I,C*]; A61K0009-52 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 58 USPATFULL on STN

Full Text

AN 2006:158680 USPATFULL
 TI Solid dosage form comprising proton pump inhibitor and suspension made
 thereof
 IN Persson, Eva, UNITED STATES
 Trofast, Eva, UNITED STATES
 PA AstraZeneca AB (U.S. corporation)
 PI US 2006134210 A1 20060622
 AI US 2005-312869 A1 20051219 (11)
 PRAI US 2004-638435P 20041222 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1002
 INCL INCLM: 424/471.000
 NCL NCLM: 424/471.000
 IC IPCI A61K0009-24 [I,A]
 IPCR A61K0009-24 [I,A]; A61K0009-24 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 15 OF 58 USPATFULL on STN

Full Text

AN 2006:136952 USPATFULL
 TI Gastric acid secretion inhibiting composition
 IN Pettersson, Anders, Lilla Edet, SWEDEN
 Nystrom, Christer, Uppsala, SWEDEN
 Hakansson, Yvonne, Uppsala, SWEDEN
 PI US 2006115530 A1 20060601
 AI US 2003-531598 A1 20031015 (10)
 WO 2003-SE1598 20031015
 20051125 PCT 371 date
 PRAI SE 2002-3065 20021016
 DT Utility
 FS APPLICATION
 LN.CNT 1343
 INCL INCLM: 424/470.000
 INCLS: 514/338.000
 NCL NCLM: 424/470.000
 NCLS: 514/338.000
 IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-26 [I,A]
 IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-00 [I,C*];
 A61K0009-00 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A];
 A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-26 [I,C]; A61K0009-26 [I,A];
 A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [I,C*];
 A61K0009-50 [I,A]; A61K0031-341 [I,C*]; A61K0031-341 [I,A];

A61K0031-4164 [I,C*]; A61K0031-4164 [I,A]; A61K0031-426 [I,C*];
A61K0031-426 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61P0001-00 [I,C*]; A61P0001-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 16 OF 58 USPATFULL on STN

Full Text

AN 2006:124305 USPATFULL
TI Taste-masked pharmaceutical compositions prepared by coacervation
IN Lai, Jin-Wang, Springboro, OH, UNITED STATES
Qian, Ken Kangyi, Cincinnati, OH, UNITED STATES
Venkatesh, Gopi M., Vandalia, OH, UNITED STATES
PA EURAND PHARMACEUTICALS LIMITED (U.S. corporation)
PI US 2006105038 A1 20060518
AI US 2005-213266 A1 20050826 (11)
PRAI US 2004-627525P 20041112 (60)
DT Utility
FS APPLICATION
LN.CNT 1147
INCL INCLM: 424/470.000
NCL NCLM: 424/470.000
IC IPCI A61K0009-26 [I,A]
IPCR A61K0009-26 [I,A]; A61K0009-26 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 17 OF 58 USPATFULL on STN

Full Text

AN 2006:92487 USPATFULL
TI Taste-masked pharmaceutical compositions
IN Venkatesh, Gopi M., Vandalia, OH, UNITED STATES
PI US 2006078614 A1 20060413
AI US 2005-248596 A1 20051012 (11)
PRAI US 2004-617737P 20041012 (60)
DT Utility
FS APPLICATION
LN.CNT 1009
INCL INCLM: 424/469.000
NCL NCLM: 424/469.000
IC IPCI A61K0009-26 [I,A]
IPCR A61K0009-26 [I,A]; A61K0009-26 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 18 OF 58 USPATFULL on STN

Full Text

AN 2006:60256 USPATFULL
TI Stable pharmaceutical formulations of benzimidazole compounds
IN Shterman, Nava, Petach Tikva, ISRAEL
Capua, Simona Di, Kfar Saba, ISRAEL
Moshe, Benny, Kfar Saba, ISRAEL
Itah, Esther, Netanya, ISRAEL
PI US 2006051421 A1 20060309
AI US 2005-153954 A1 20050615 (11)
PRAI US 2004-580273P 20040615 (60)
US 2004-588233P 20040714 (60)
US 2004-591784P 20040727 (60)
DT Utility
FS APPLICATION
LN.CNT 913
INCL INCLM: 424/472.000
INCLS: 514/338.000
NCL NCLM: 424/472.000
NCLS: 514/338.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0009-24 [I,A]
IPCR A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0009-24 [I,C];
A61K0009-24 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 19 OF 58 USPATFULL on STN

Full Text

AN 2006:53564 USPATFULL
TI Controlled regional oral delivery
IN Jacob, Jules S., Taunton, MA, UNITED STATES

Mathiowitz, Edith, Brookline, MA, UNITED STATES
 Nangia, Avinash, Wrentham, MA, UNITED STATES
 Shaked, Ze'ev, San Antonio, TX, UNITED STATES
 Moslemy, Peyman, Providence, RI, UNITED STATES
 PA Spherics, Inc. (U.S. corporation)
 PI US 2006045865 A1 20060302
 AI US 2005-214206 A1 20050828 (11)
 PRAI US 2004-604990P 20040827 (60)
 US 2004-605198P 20040827 (60)
 US 2004-605199P 20040827 (60)
 US 2004-605200P 20040827 (60)
 US 2004-605201P 20040827 (60)
 US 2004-607905P 20040908 (60)
 US 2005-650191P 20050204 (60)
 US 2005-650375P 20050204 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2229
 INCL INCLM: 424/078.270
 NCL NCLM: 424/078.270
 IC IPCI A61K0031-74 [I,A]
 IPCR A61K0031-74 [I,A]; A61K0031-74 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 20 OF 58 USPATFULL on STN

Full Text

AN 2006:27533 USPATFULL
 TI Composition comprising a benzimidazole and process for its manufacture
 IN Seth, Pawan, Irvine, CA, UNITED STATES
 PI US 2006024362 A1 20060202
 AI US 2004-901898 A1 20040729 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 648
 INCL INCLM: 424/464.000
 INCLS: 514/394.000
 NCL NCLM: 424/464.000
 NCLS: 514/394.000
 IC IPCI A61K0009-20 [I,A]; A61K0031-4184 [I,A]; A61K0031-4164 [I,C*]
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C]; A61K0031-4164 [I,C];
 A61K0031-4184 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 21 OF 58 USPATFULL on STN

Full Text

AN 2006:15490 USPATFULL
 TI Controlled release preparation
 IN Akiyama, Yohko, Osaka-shi Osaka, JAPAN
 Kurasawa, Takashi, Osaka-shi Osaka, JAPAN
 Bando, Hiroto, Osaka-shi Osaka, JAPAN
 Nagahara, Naoki, Osaka-shi Osaka, JAPAN
 PI US 2006013868 A1 20060119
 AI US 2003-531069 A1 20031015 (10)
 WO 2003-JP13155 20031015
 20050411 PCT 371 date
 PRAI JP 2002-301876 20021016
 JP 2003-66336 20030312
 DT Utility
 FS APPLICATION
 LN.CNT 7380
 INCL INCLM: 424/458.000
 NCL NCLM: 424/458.000
 IC IPCI A61K0009-54 [I,A]; A61K0009-52 [I,C*]
 IPCR A61K0009-52 [I,C]; A61K0009-54 [I,A]; A61K0009-20 [I,C*];
 A61K0009-20 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 22 OF 58 USPATFULL on STN

Full Text

AN 2005:247176 USPATFULL

TI Stable pharmaceutical composition comprising an acid labile drug
 IN Di Capua, Simona, Kfar Saba, ISRAEL
 Shterman, Nava, Petach Tikva, ISRAEL
 Ari-Pardo, Limor, Israel, ISRAEL
 Itah, Esther, Netanya, ISRAEL
 PI US 2005214371 A1 20050929
 AI US 2005-68881 A1 20050302 (11)
 PRAI US 2004-549653P 20040303 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1099
 INCL INCLM: 424/472.000
 INCLS: 514/338.000
 NCL NCLM: 424/472.000
 NCLS: 514/338.000
 IC [7]
 ICM A61K031-4439
 ICS A61K009-24
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
 [ICS,7]
 IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 23 OF 58 USPATFULL on STN

Full Text

AN 2005:240133 USPATFULL
 TI Gastrointestinal-specific multiple drug release system
 IN Tsutsumi, Keiko, Norman, OK, UNITED STATES
 Chu, James S., Norman, OK, UNITED STATES
 PA Yamanouchi Pharma Technologies, Inc., Norman, OK, UNITED STATES (U.S.
 corporation)
 PI US 2005208133 A1 20050922
 AI US 2005-46517 A1 20050127 (11)
 PRAI US 2004-540682P 20040129 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1837
 INCL INCLM: 424/472.000
 NCL NCLM: 424/472.000
 IC [7]
 ICM A61K009-48
 ICS A61K009-24
 IPCI A61K0009-48 [ICM,7]; A61K0009-24 [ICS,7]
 IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-48 [I,C*];
 A61K0009-48 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 24 OF 58 USPATFULL on STN

Full Text

AN 2005:74741 USPATFULL
 TI Stable drug form for oral administration with benzimidazole derivatives
 as active ingredient and process for the preparation thereof
 IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
 Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
 Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
 Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
 Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
 Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
 PI US 2005064035 A1 20050324
 AI US 2003-665081 A1 20030916 (10)
 RLI Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, GRANTED,
 Pat. No. US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23
 Dec 1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27
 Jun 1997, UNKNOWN
 PRAI DE 1996-19626045 19960628
 DT Utility
 FS APPLICATION
 LN.CNT 980
 INCL INCLM: 424/472.000
 INCLS: 514/338.000

NCL NCLM: 424/472.000
NCLS: 514/338.000
IC [7]
ICM A61K031-4439
ICS A61K009-24
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24
[ICS,7]
IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 25 OF 58 USPATFULL on STN

Full Text

AN 2005:3902 USPATFULL
TI Granules containing acid-unstable chemical in large amount
IN Shimizu, Toshihiro, Itami-shi, JAPAN
Nakano, Yoshinori, Takarazuka-shi, JAPAN
PI US 2005003005 A1 20050106
AI US 2004-492690 A1 20040415 (10)
WO 2002-JP10720 20021016
PRAI JP 2001-319444 20011017
DT Utility
FS APPLICATION
LN.CNT 1331
INCL INCLM: 424/471.000
INCLS: 514/338.000
NCL NCLM: 424/471.000
NCLS: 514/338.000
IC [7]
ICM A61K009-24
ICS A61K031-4439
IPCI A61K0009-24 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427
[ICS,7,C*]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-26 [I,C*];
A61K0009-26 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-4164 [I,C*];
A61K0031-4184 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 26 OF 58 USPATFULL on STN

Full Text

AN 2004:334292 USPATFULL
TI Oral multi-functional pharmaceutical capsule preparations of proton pump
inhibitors
IN Odidi, Isa, Toronto, CANADA
Odidi, Amina, Toronto, CANADA
PI US 2004265370 A1 20041230
AI US 2004-861809 A1 20040604 (10)
PRAI US 2003-482439P 20030626 (60)
US 2004-548903P 20040302 (60)
DT Utility
FS APPLICATION
LN.CNT 1317
INCL INCLM: 424/452.000
INCLS: 424/454.000
NCL NCLM: 424/452.000
NCLS: 424/454.000
IC [7]
ICM A61K009-48
IPCI A61K0009-48 [ICM,7]
IPCR A61K0009-16 [N,C*]; A61K0009-16 [N,A]; A61K0009-20 [I,C*];
A61K0009-20 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0031-00 [I,C*];
A61K0031-00 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 27 OF 58 USPATFULL on STN

Full Text

AN 2004:279911 USPATFULL

TI Pharmaceutical formulation comprising a proton pump inhibitor and antacids
 IN Criere, Bruno, Gragny, FRANCE
 Nouri, Nourredine, Cannes, FRANCE
 Pilbrant, Ake, Kungsbacka, SWEDEN
 Suplie, Pascal, Montauze, FRANCE
 Zuccarelli, Jean-Marc, Antibes, FRANCE
 PI US 2004219211 A1 20041104
 AI US 2004-484064 A1 20040526 (10)
 WO 2002-SE1370 20020710
 PRAI EP 2001-401896 20010716
 DT Utility
 FS APPLICATION
 LN.CNT 997
 INCL INCLM: 424/469.000
 INCLS: 514/338.000
 NCL NCLM: 424/469.000
 NCLS: 514/338.000
 IC [7]
 ICM A61K009-26
 IPCI A61K0009-26 [ICM,7]
 IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-16 [I,C*];
 A61K0009-16 [I,A]; A61K0009-20 [N,C*]; A61K0009-20 [N,A];
 A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-50 [N,C*];
 A61K0009-50 [N,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 A61K0033-06 [I,C*]; A61K0033-06 [I,A]; A61K0033-08 [I,A];
 A61K0033-10 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
 A61K0047-02 [I,C*]; A61K0047-02 [I,A]; A61K0047-04 [I,A];
 A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-12 [I,C*];
 A61K0047-12 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A];
 A61K0047-16 [I,C*]; A61K0047-16 [I,A]; A61K0047-20 [I,C*];
 A61K0047-20 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A];
 A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-42 [I,C*];
 A61K0047-42 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 28 OF 58 USPATFULL on STN

Full Text

AN 2004:215056 USPATFULL
 TI Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
 IN Niecestro, Robert, Pocono Pines, PA, UNITED STATES
 Kositprapa, Unchalee, Davie, FL, UNITED STATES
 Oh, Yoon, Pembroke Pines, FL, UNITED STATES
 Nangia, Avinash, Weston, FL, UNITED STATES
 Cardinal, John R., Tamarac, FL, UNITED STATES
 Hahn, Elliot F., North Miami Beach, FL, UNITED STATES
 PI US 2004166162 A1 20040826
 AI US 2004-761805 A1 20040121 (10)
 PRAI US 2003-442337P 20030124 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1055
 INCL INCLM: 424/472.000
 INCLS: 514/339.000
 NCL NCLM: 424/472.000
 NCLS: 514/339.000
 IC [7]
 ICM A61K031-4439
 ICS A61K009-24
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-24 [ICS,7]
 IPCR A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 29 OF 58 USPATFULL on STN

Full Text

AN 2004:171514 USPATFULL
 TI Method of manufacturing tablet
 IN Yamamoto, Keiichi, Hyogo, JAPAN
 Mizukami, Yoshio, Hyogo, JAPAN

Izutsu, Daisuke, Dublin, IRELAND

PI US 2004131675 A1 20040708

AI US 2003-477478 A1 20031112 (10)

WO 2002-JP6087 20020619

PRAI JP 2001-186433 20010620

DT Utility

FS APPLICATION

LN.CNT 1642

INCL INCLM: 424/465.000

INCLS: 264/109.000; 264/123.000

NCL NCLM: 424/465.000

NCLS: 264/109.000; 264/123.000

IC [7]

ICM B29C067-24

ICS A61K009-20

IPCI B29C067-24 [ICM,7]; A61K0009-20 [ICS,7]

IPCR A61J0003-00 [I,C*]; A61J0003-00 [I,A]; A61J0003-10 [I,C*];

A61J0003-10 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];

A61K0009-24 [I,C*]; A61K0009-24 [I,A]; A61K0009-50 [N,C*];

A61K0009-50 [N,A]; B30B0011-02 [I,C*]; B30B0011-08 [I,A];

B30B0015-34 [I,C*]; B30B0015-34 [I,A]

L15 ANSWER 30 OF 58 USPATFULL on STN

Full Text

AN 2004:108112 USPATFULL

TI Methods for treatment of helicobacter pylori-associated disorders

IN Chowders, Yehuda, Moshav Zofit, ISRAEL

Glozman, Sabina, Rehovot, ISRAEL

PI US 2004082514 A1 20040429

US 7271146 B2 20070918

AI US 2003-682937 A1 20031014 (10)

PRAI IL 2002-152289 20021014

DT Utility

FS APPLICATION

LN.CNT 1186

INCL INCLM: 514/012.000

INCLS: 514/338.000

NCL NCLM: 514/002.000; 514/012.000

NCLS: 424/009.100; 435/007.100; 435/243.000; 514/012.000; 514/017.000;

514/018.000; 530/300.000; 514/338.000

IC [7]

ICM A61K038-17

ICS A61K031-4439

IPCI A61K0038-17 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427

[ICS,7,C*]

IPCI-2 A61K0038-00 [I,A]; A61K0049-00 [I,A]

IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K [I,S]; A61K0031-4427

[I,C*]; A61K0031-4439 [I,A]; A61K0038-17 [I,C*]; A61K0038-17

[I,A]; A61K0038-22 [I,C*]; A61K0038-22 [I,A]; A61K0049-00 [I,C];

A61K0049-00 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];

A61P0031-00 [I,C*]; A61P0031-04 [I,A]; C07K [I,S]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 31 OF 58 USPATFULL on STN

Full Text

AN 2004:82352 USPATFULL

TI Maximizing effectiveness of substances used to improve health and well

being

IN Hermelin, Victor M., Chesterfield, MI, UNITED STATES

PI US 2004062802 A1 20040401

AI US 2003-644041 A1 20030820 (10)

RLI Continuation of Ser. No. US 1999-475992, filed on 30 Dec 1999, PENDING

Continuation-in-part of Ser. No. US 1999-323158, filed on 1 Jun 1999,

GRANTED, Pat. No. US 6214379 Continuation of Ser. No. US 1998-53487,

filed on 2 Apr 1998, GRANTED, Pat. No. US 5945123

DT Utility

FS APPLICATION

LN.CNT 3143

INCL INCLM: 424/468.000

NCL NCLM: 424/468.000

IC [7]

ICM A61K009-22

IPCI A61K0009-22 [ICM,7]
 IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0031-275 [I,C*];
 A61K0031-277 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A];
 A61K0031-4458 [I,C*]; A61K0031-4458 [I,A]; A61K0031-517 [I,C*];
 A61K0031-517 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A];
 A61K0031-551 [I,C*]; A61K0031-5513 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 32 OF 58 USPATFULL on STN

Full Text

AN 2004:57067 USPATFULL
 TI Stable oral formulation containing benzimidazole derivative
 IN Vanderbist, Francis, Bruxelles, BELGIUM
 Sereno, Antonio, Melsbroek, BELGIUM
 Baudier, Philippe, Uccle, BELGIUM
 PI US 2004043069 A1 20040304
 AI US 2003-399482 A1 20030418 (10)
 WO 2001-BE184 20011018
 PRAI WO 2000-BE126 20001020
 DT Utility
 FS APPLICATION
 LN.CNT 548
 INCL INCLM: 424/471.000
 NCL NCLM: 424/471.000
 IC [7]

ICM A61K009-24
 IPCI A61K0009-24 [ICM,7]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-28 [I,C*];
 A61K0009-28 [I,A]; A61K0031-352 [I,C*]; A61K0031-355 [I,A];
 A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 33 OF 58 USPATFULL on STN

Full Text

AN 2004:38201 USPATFULL
 TI Enteric coated stable oral pharmaceutical composition of acid unstable
 drug and process for preparing the same
 IN Deshpande, Jayant Venkatesh, Maharashtra, INDIA
 Gupte, Vandana Sandeep, Maharashtra, INDIA
 Kadam, Vaishali Madhukar, Maharashtra, INDIA
 Gosar, Chandrakant Thakarsi, Maharashtra, INDIA
 Deshmukh, Satish Ramachandra, Maharashtra, INDIA
 Gupte, Rajan Vitthal, Maharashtra, INDIA
 Tamhankar, Vijay Ramachandra, Maharashtra, INDIA
 PA Kopran Research Laboratories Limited, Maharashtra, INDIA (non-U.S.
 corporation)
 PI US 2004028737 A1 20040212
 AI US 2002-216315 A1 20020812 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 612
 INCL INCLM: 424/474.000
 INCLS: 514/338.000
 NCL NCLM: 424/474.000
 NCLS: 514/338.000
 IC [7]

ICM A61K031-4439
 ICS A61K009-16; A61K009-50
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-16
 [ICS,7]; A61K0009-50 [ICS,7]
 IPCR A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-50 [I,C*];
 A61K0009-50 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 34 OF 58 USPATFULL on STN

Full Text

AN 2004:30709 USPATFULL
 TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and
 a NSAID
 IN Depui, Helene, Goteborg, SWEDEN
 Lundberg, Per, Molndal, SWEDEN

PI US 2004022846 A1 20040205
 AI US 2003-620000 A1 20030714 (10)
 RLI Continuation of Ser. No. US 2002-90882, filed on 4 Mar 2002, GRANTED,
 Pat. No. US 6613354 Continuation of Ser. No. US 1999-471958, filed on 23
 Dec 1999, GRANTED, Pat. No. US 6365184 Continuation of Ser. No. US
 1997-793078, filed on 13 Feb 1997, ABANDONED A 371 of International Ser.
 No. WO 1996-SE1735, filed on 20 Dec 1996, UNKNOWN
 PRAI SE 1996-70 19960108
 DT Utility
 FS APPLICATION
 LN.CNT 1465
 INCL INCLM: 424/452.000
 INCLS: 424/465.000; 514/338.000
 NCL NCLM: 424/452.000
 NCLS: 424/465.000; 514/338.000
 IC [7]
 ICM A61K031-4439
 ICS A61K009-48; A61K009-20
 IPCI A61K0031-4439 [ICM, 7]; A61K0031-4427 [ICM, 7, C*]; A61K0009-48
 [ICS, 7]; A61K0009-20 [ICS, 7]
 IPCR A61K0009-20 [I, C*]; A61K0009-20 [I, A]; A61K0009-24 [I, C*];
 A61K0009-24 [I, A]; A61K0009-28 [I, C*]; A61K0009-28 [I, A];
 A61K0009-50 [I, C*]; A61K0009-50 [I, A]; A61K0045-00 [I, C*];
 A61K0045-06 [I, A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 35 OF 58 USPATFULL on STN

Full Text

AN 2003:288260 USPATFULL
 TI Stable oral pharmaceutical dosage forms
 IN Chen, Jivn-Ren, Shreveport, LA, UNITED STATES
 PA Sage Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2003203018 A1 20031030
 US 7041316 B2 20060509
 AI US 2003-422338 A1 20030424 (10)
 RLI Division of Ser. No. US 1998-141476, filed on 27 Aug 1998, PENDING
 Continuation-in-part of Ser. No. US 1997-950432, filed on 15 Oct 1997,
 ABANDONED
 PRAI WO 1998-US9449 19980508
 US 1997-46089P 19970509 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 633
 INCL INCLM: 424/452.000
 NCL NCLM: 424/463.000; 424/452.000
 NCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
 424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
 IC [7]
 ICM A61K009-48
 IPCI A61K0009-48 [ICM, 7]
 IPCI-2 A61L0009-48 [I, A]; A61L0009-64 [I, A]; A61L0009-20 [I, A];
 A61L0009-18 [I, C*]; A61L0009-32 [I, A]; A61L0009-14 [I, A]
 IPCR A61K0009-30 [I, C]; A61K0009-32 [I, A]; A61K0009-28 [I, C*];
 A61K0009-28 [I, A]; A61K0009-48 [I, C]; A61K0009-48 [I, A];
 A61K0009-52 [I, C]; A61K0009-64 [I, A]; A61K0031-4164 [I, C*];
 A61K0031-4184 [I, A]; A61K0031-4427 [I, C*]; A61K0031-4439 [I, A];
 A61L0009-14 [I, C]; A61L0009-18 [I, C]; A61L0009-20 [I, A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 36 OF 58 USPATFULL on STN

Full Text

AN 2003:250574 USPATFULL
 TI Symptomatic relief of gastrointestinal disorders
 IN Luzzatti, Renzo, Weston, FL, UNITED STATES
 PI US 2003175360 A1 20030918
 AI US 2002-79569 A1 20020222 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 2408
 INCL INCLM: 424/653.000
 INCLS: 424/682.000; 424/691.000; 514/304.000; 514/503.000; 514/537.000
 NCL NCLM: 424/653.000

NCLS: 424/682.000; 424/691.000; 514/304.000; 514/503.000; 514/537.000
 IC [7]
 ICM A61K031-46
 ICS A61K031-29; A61K033-08; A61K033-06; A61K033-24
 IPCI A61K0031-46 [ICM,7]; A61K0031-29 [ICS,7]; A61K0031-28 [ICS,7,C*];
 A61K0033-08 [ICS,7]; A61K0033-06 [ICS,7]; A61K0033-24 [ICS,7]
 IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0033-06 [I,C*];
 A61K0033-06 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0001-00 [I,C*];
 A61P0001-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 37 OF 58 USPATFULL on STN

Full Text

AN 2003:209868 USPATFULL
 TI Pharmaceutical formulation for acid-labile compounds
 IN Chen, Chih-Ming, Davie, FL, United States
 Chou, Joseph, Coral Springs, FL, United States
 Kositprapa, Unchalee, Fort Lauderdale, FL, United States
 PA Andrx Pharmaceuticals L.L.C., Davie, FL, United States (U.S.
 corporation)
 PI US 6602522 B1 20030805
 AI US 2000-597206 20000620 (9)
 RLI Continuation-in-part of Ser. No. US 1999-335575, filed on 18 Jun 1999,
 now patented, Pat. No. US 6077541 Division of Ser. No. US 1997-970489,
 filed on 14 Nov 1997, now patented, Pat. No. US 6096340
 Continuation-in-part of Ser. No. US 1998-143167, filed on 28 Aug 1998,
 now patented, Pat. No. US 6174548
 DT Utility
 FS GRANTED
 LN.CNT 508
 INCL INCLM: 424/480.000
 INCLS: 424/474.000; 424/475.000; 424/476.000; 424/479.000
 NCL NCLM: 424/480.000
 NCLS: 424/474.000; 424/475.000; 424/476.000; 424/479.000
 IC [7]
 ICM A61K009-36
 ICS A61K009-14; A61K009-24; A61K009-28; A61K009-30
 IPCI A61K0009-36 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-24 [ICS,7];
 A61K0009-28 [ICS,7]; A61K0009-30 [ICS,7]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-28 [I,C*];
 A61K0009-28 [I,A]; A61K0009-30 [I,C*]; A61K0009-30 [I,A];
 A61K0009-36 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
 EXF 424/480; 424/479; 424/475; 424/474; 424/476
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 38 OF 58 USPATFULL on STN

Full Text

AN 2003:187448 USPATFULL
 TI Pharmaceutical formulations containing a non-steroidal antiinflammatory
 drug and a proton pump inhibitor
 IN Chen, Chih-Ming, Davie, FL, UNITED STATES
 Kositprapa, Unchalee, Davie, FL, UNITED STATES
 PI US 2003129235 A1 20030710
 US 6869615 B2 20050322
 AI US 2002-282820 A1 20021028 (10)
 RLI Continuation of Ser. No. US 2000-659222, filed on 11 Sep 2000, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 1271
 INCL INCLM: 424/470.000
 NCL NCLM: 424/469.000; 424/470.000
 NCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000;
 424/468.000; 424/470.000; 424/474.000; 424/489.000; 424/490.000
 IC [7]
 ICM A61K009-26
 IPCI A61K0009-26 [ICM,7]
 IPCI-2 A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-26 [ICS,7];
 A61K0009-28 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A];

A61K0009-28 [N,C*]; A61K0009-28 [N,A]; A61K0009-30 [I,C*];
 A61K0009-30 [I,A]; A61K0009-32 [I,A]; A61K0009-34 [I,A];
 A61K0009-36 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
 A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0009-52 [I,C*];
 A61K0009-54 [I,A]; A61K0009-58 [I,A]; A61K0009-60 [I,A];
 A61K0009-62 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A];
 A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-44 [I,C*];
 A61K0031-44 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-10 [I,C*];
 A61K0047-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
 A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0029-00 [I,C*];
 A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 39 OF 58 USPATFULL on STN

Full Text

AN 2003:95840 USPATFULL
 TI Pharmaceutical formulations containing a non-steroidal antiinflammatory
 drug and a proton pump inhibitor
 IN Chen, Chih-Ming, Davie, FL, United States
 Kositprapa, Unchalee, Davie, FL, United States
 PA Andrx Corporation, Davie, FL, United States (U.S. corporation)
 PI US 6544556 B1 20030408
 AI US 2000-659222 20000911 (9)
 DT Utility
 FS GRANTED
 LN.CNT 1236
 INCL INCLM: 424/469.000
 INCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/464.000;
 424/465.000; 424/470.000; 424/472.000
 NCL NCLM: 424/469.000
 NCLS: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/464.000;
 424/465.000; 424/470.000; 424/472.000
 IC [7]
 ICM A61K009-20
 ICS A61K009-22; A61K009-24; A61K009-26; A61K009-54
 IPCI A61K0009-20 [ICM,7]; A61K0009-22 [ICS,7]; A61K0009-24 [ICS,7];
 A61K0009-26 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A];
 A61K0009-28 [N,C*]; A61K0009-28 [N,A]; A61K0009-30 [I,C*];
 A61K0009-30 [I,A]; A61K0009-32 [I,A]; A61K0009-34 [I,A];
 A61K0009-36 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
 A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0009-52 [I,C*];
 A61K0009-54 [I,A]; A61K0009-58 [I,A]; A61K0009-60 [I,A];
 A61K0009-62 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A];
 A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-44 [I,C*];
 A61K0031-44 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-10 [I,C*];
 A61K0047-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A];
 A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0029-00 [I,C*];
 A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
 EXF 424/451; 424/455; 424/456; 424/464; 424/468; 424/469; 424/470; 424/477;
 424/480; 424/481; 424/482; 424/489; 424/493; 424/494; 424/495; 424/496;
 424/497; 424/452; 424/472; 424/457; 424/458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 40 OF 58 USPATFULL on STN

Full Text

AN 2002:279721 USPATFULL
 TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and
 a NSAID
 IN Depui, Helene, Goteborg, SWEDEN
 Lundberg, Per, Molndal, SWEDEN
 PA AstraZeneca AB. (non-U.S. corporation)
 PI US 2002155153 A1 20021024
 US 6613354 B2 20030902
 AI US 2002-90882 A1 20020304 (10)
 RLI Continuation of Ser. No. US 1999-471958, filed on 23 Dec 1999, GRANTED,
 Pat. No. US 6365184 Continuation of Ser. No. US 1997-793078, filed on 13
 Feb 1997, ABANDONED A 371 of International Ser. No. WO 1996-SE1735,
 filed on 20 Dec 1996, UNKNOWN

PRAI SE 1996-70 19960108
 DT Utility
 FS APPLICATION
 LN.CNT 1497
 INCL INCLM: 424/452.000
 INCLS: 424/465.000; 514/338.000
 NCL NCLM: 424/458.000; 424/452.000
 NCLS: 424/451.000; 424/452.000; 424/457.000; 424/465.000; 514/338.000
 IC [7]
 ICM A61K031-4439
 ICS A61K009-48; A61K009-20
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-48
 [ICS,7]; A61K0009-20 [ICS,7]
 IPCI-2 A61K0009-48 [ICM,7]; A61K0009-52 [ICS,7]; A61K0009-54 [ICS,7];
 A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
 A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0045-00 [I,C*];
 A61K0045-06 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 41 OF 58 USPATFULL on STN

Full Text

AN 2002:258467 USPATFULL
 TI Orally disintegrable tablets
 IN Shimizu, Toshihiro, Itami-shi, JAPAN
 Morimoto, Shuji, Osaka, JAPAN
 Tabata, Tetsuro, Osaka, JAPAN
 PI US 2002142034 A1 20021003
 AI US 2001-17755 A1 20011030 (10)
 RLI Continuation of Ser. No. US 1999-355781, filed on 4 Aug 1999, GRANTED,
 Pat. No. US 6328994 A 371 of International Ser. No. WO 1999-JP2548,
 filed on 17 May 1999, UNKNOWN
 PRAI JP 1998-135472 19980518
 JP 1998-219266 19980803
 JP 1998-222151 19980805
 JP 1999-5144 19990112
 JP 1999-15851 19990125
 DT Utility
 FS APPLICATION
 LN.CNT 2241
 INCL INCLM: 424/470.000
 INCLS: 514/338.000
 NCL NCLM: 424/470.000
 NCLS: 514/338.000
 IC [7]
 ICM A61K031-4439
 ICS A61K009-26; A61K009-14
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-26
 [ICS,7]; A61K0009-14 [ICS,7]
 IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*];
 A61K0009-20 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 42 OF 58 USPATFULL on STN

Full Text

AN 2002:115818 USPATFULL
 TI Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl]
 sulfinyl benzimidazole having anti-ulcer activity and a process for the
 preparation of such formulation
 IN Henriksen, Kristian Lund, S.o slashed.borg, DENMARK
 Kann, Helle, Frederiksberg, DENMARK
 S.o slashed.rensen, Karen Eichstedt, Valby, DENMARK
 Pedersen, S.o slashed.ren Bols, Hvidovre, DENMARK
 PA A/S GEA Farmaceutisk Fabrik, Frederiksberg, DENMARK (non-U.S.
 corporation)
 PI US 6391342 B1 20020521
 WO 9948498 19990930
 AI US 2000-646486 20000919 (9)
 WO 1999-DK137 19990317
 20000919 PCT 371 date

PRAI DK 1998-397 19980320
 DT Utility
 FS GRANTED
 LN.CNT 763
 INCL INCLM: 424/490.000
 INCLS: 424/457.000; 424/458.000; 424/456.000; 424/489.000; 424/498.000
 NCL NCLM: 424/490.000
 NCLS: 424/456.000; 424/457.000; 424/458.000; 424/489.000; 424/498.000
 IC [7]
 ICM A61K009-50
 ICS A61K009-16; A61K009-52; A61K009-64; A61K009-54
 IPCI A61K0009-50 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-52 [ICS,7];
 A61K0009-64 [ICS,7]; A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
 A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0009-64 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
 EXF 424/490; 424/457; 424/458; 424/456; 424/502; 424/489
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 43 OF 58 USPATFULL on STN

Full Text

AN 2002:105711 USPATFULL
 TI Stable drug from for oral administration with benzimidazole derivatives
 as active ingredient and process for the preparation thereof
 IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
 Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
 Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
 Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
 Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
 Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
 PI US 2002054913 A1 20020509
 US 6623759 B2 20030923
 AI US 2001-947166 A1 20010905 (9)
 RLI Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, ABANDONED
 PRAI DE 1996-19626045 19960628
 DT Utility
 FS APPLICATION
 LN.CNT 989
 INCL INCLM: 424/490.000
 NCL NCLM: 424/480.000; 424/490.000
 NCLS: 424/461.000; 424/462.000; 424/472.000; 424/475.000; 424/482.000;
 424/490.000; 424/494.000; 424/497.000; 514/772.300; 514/781.000
 IC [7]
 ICM A61K009-16
 ICS A61K009-50
 IPCI A61K0009-16 [ICM,7]; A61K0009-50 [ICS,7]
 IPCI-2 A61K0009-24 [ICM,7]; A61K0009-32 [ICS,7]; A61K0009-36 [ICS,7];
 A61K0009-30 [ICS,7,C*]; A61K0009-58 [ICS,7]; A61K0009-62 [ICS,7];
 A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-30 [I,C*]; A61K0009-32 [I,A]; A61K0009-36 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
 A61K0009-58 [I,A]; A61K0009-62 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 44 OF 58 USPATFULL on STN

Full Text

AN 2002:69628 USPATFULL
 TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and
 a NSAID
 IN Depui, Helene, Goteborg, SWEDEN
 Lundberg, Per, Molndal, SWEDEN
 PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
 PI US 6365184 B1 20020402
 AI US 1999-471958 19991223 (9)
 RLI Continuation of Ser. No. US 793078, now abandoned
 PRAI SE 1996-70 19960108
 DT Utility
 FS GRANTED
 LN.CNT 1319
 INCL INCLM: 424/469.000
 INCLS: 424/469.000; 424/468.000; 424/464.000; 424/465.000; 424/472.000;

224/473.000; 224/471.000; 224/470.000; 224/490.000; 224/493.000;
224/494.000; 514/338.000

NCL NCLM: 224/469.000
NCLS: 224/464.000; 224/465.000; 224/468.000; 224/470.000; 224/471.000;
224/472.000; 224/473.000; 224/490.000; 224/493.000; 224/494.000;
514/338.000

IC [7]
ICM A61K009-36
ICS A61K009-26
IPCI A61K0009-36 [ICM,7]; A61K0009-30 [ICM,7,C*]; A61K0009-26 [ICS,7]
IPCR C07D0401-00 [I,C*]; C07D0401-12 [I,A]; A61K0009-20 [I,C*];
A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0009-28 [I,C*];
A61K0009-28 [I,A]; A61K0009-30 [I,C*]; A61K0009-36 [I,A];
A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [I,C*];
A61K0009-50 [I,A]; A61K0009-52 [I,C*]; A61K0009-54 [I,A];
A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0031-4164 [I,C*];
A61K0031-4184 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]

EXF 224/464; 224/465; 224/472; 224/99; 224/473; 224/471; 224/468-469;
224/470; 224/474; 224/493; 224/494; 224/490; 514/338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 45 OF 58 USPATFULL on STN

Full Text

AN 2002:29141 USPATFULL
TI Method for preparing an oral formulation containing acid-sensitive drugs
and oral formulation made thereby
IN Hsiao, Fang-Hsiung, Tainan Hsien, TAIWAN, PROVINCE OF CHINA
Lin, Chien-Chu, Tainan Hsien, TAIWAN, PROVINCE OF CHINA
Changchien, Ya-Ching, Kaohsiung, TAIWAN, PROVINCE OF CHINA
PA Standard Chem. & Pharm. Co., Ltd., Tainan, TAIWAN, PROVINCE OF CHINA
(non-U.S. corporation)
PI US 6346269 B1 20020212
AI US 2000-567083 20000508 (9)
DT Utility
FS GRANTED
LN.CNT 703
INCL INCLM: 224/472.000
INCLS: 224/464.000; 224/465.000; 224/451.000; 224/458.000
NCL NCLM: 224/472.000
NCLS: 224/451.000; 224/458.000; 224/464.000; 224/465.000
IC [7]
ICM A61K009-24
ICS A61K009-20; A61K009-48; A61K009-54
IPCI A61K0009-24 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-48 [ICS,7];
A61K0009-54 [ICS,7]; A61K0009-52 [ICS,7,C*]
IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
A61K0009-54 [I,A]

EXF 224/464; 224/465; 224/458; 224/451; 224/472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 46 OF 58 USPATFULL on STN

Full Text

AN 2001:226274 USPATFULL
TI Orally disintegrable tablets
IN Shimizu, Toshihiro, Itami, Japan
Morimoto, Shuji, Suita, Japan
Tabata, Tetsuro, Suita, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 6328994 B1 20011211
WO 9959544 19991125
AI US 1999-355781 19990804 (9)
WO 1999-JP2548 19990517
19990804 PCT 371 date
19990804 PCT 102(e) date
PRAI JP 1998-135472 19980518
JP 1998-219266 19980803
JP 1998-222151 19980805
JP 1998-344810 19981029
JP 1999-5144 19990112

JP 1999-15851 19990125
DT Utility
FS GRANTED
LN.CNT 2214
INCL INCLM: 424/489.000
INCLS: 424/464.000; 424/465.000; 424/466.000; 424/490.000; 424/493.000
NCL NCLM: 424/489.000
NCLS: 424/464.000; 424/465.000; 424/466.000; 424/490.000; 424/493.000
IC [7]
ICM A61K009-14
ICS A61K009-20; A61K009-46; A61K009-16
IPCI A61K0009-14 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-46 [ICS,7];
A61K0009-16 [ICS,7]
IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-00 [I,C*];
A61K0009-00 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61P0001-00 [I,C*];
A61P0001-04 [I,A]
EXF 424/464; 424/465; 424/466; 424/489; 424/490; 424/493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 47 OF 58 USPATFULL on STN

Full Text

AN 2001:105030 USPATFULL
TI STABLE ORAL PHARMACEUTICAL DOSAGE FORMS
IN CHEN, JIVN-REN, SHREVEPORT, LA, United States
PI US 2001006649 A1 20010705
US 6726927 B2 20040427
AI US 1998-141476 A1 19980827 (9)
RLI Continuation of Ser. No. US 1997-950432, filed on 15 Oct 1997, ABANDONED
A 371 of International Ser. No. WO 1998-US9449, filed on 8 May 1998,
UNKNOWN
PRAI US 1997-46089P 19970509 (60)
DT Utility
FS APPLICATION
LN.CNT 633
INCL INCLM: 424/400.000
NCL NCLM: 424/463.000; 424/400.000
NCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
IC [7]
ICM A61K009-00
IPCI A61K0009-00 [ICM,7]
IPCI-2 A61L0009-48 [ICM,7]; A61L0009-64 [ICS,7]; A61L0009-20 [ICS,7];
A61L0009-18 [ICS,7,C*]; A61L0009-32 [ICS,7]; A61L0009-14 [ICS,7]
IPCR A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-48 [I,A];
A61K0009-48 [I,C*]; A61K0031-4164 [I,C*]; A61K0031-4184 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 48 OF 58 USPATFULL on STN

Full Text

AN 2001:67211 USPATFULL
TI Orally administered pharmaceutical formulations of benzimidazole
derivatives and the method of preparing the same
IN Lee, Fang-Yu, Taichung, Taiwan, Province of China
Chen, Shan-chiung, Taichung, Taiwan, Province of China
Kuo, Han-Chiang, Taichung, Taiwan, Province of China
PA Carlsbad Technology, Inc., Carlsbad, CA, United States (U.S.
corporation)
PI US 6228400 B1 20010508
AI US 2000-488406 20000119 (9)
PRAI US 1999-156394P 19990928 (60)
DT Utility
FS Granted
LN.CNT 752
INCL INCLM: 424/489.000
INCLS: 424/451.000; 424/452.000; 424/490.000; 424/493.000; 424/494.000;
514/277.000; 514/336.000; 514/337.000; 514/338.000
NCL NCLM: 424/489.000
NCLS: 424/451.000; 424/452.000; 424/490.000; 424/493.000; 424/494.000;
514/277.000; 514/336.000; 514/337.000; 514/338.000
IC [7]

ICM A61K009-14
 ICS A61K009-48; A61K009-16; A01N043-40
 IPCI A61K0009-14 [ICM,7]; A61K0009-48 [ICS,7]; A61K0009-16 [ICS,7];
 A01N0043-40 [ICS,7]; A01N0043-34 [ICS,7,C*]
 IPCR A61K0009-50 [I,A]; A61K0009-50 [I,C*]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 EXF 514/277; 514/336; 514/337; 514/338; 424/451; 424/452; 424/489; 424/490;
 424/493; 424/494
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 49 OF 58 USPATFULL on STN

Full Text

AN 2000:167547 USPATFULL
 TI Composition containing an acid-labile benzimidazole and process for its
 preparation
 IN Seth, Pawan, Irvine, CA, United States
 PA Pharma Pass LLC, Irvine, CA, United States (U.S. corporation)
 PI US 6159499 20001212
 WO 9712580 19970410
 AI US 1998-43663 19981020 (9)
 WO 1996-IB1054 19960923
 19981020 PCT 371 date
 19981020 PCT 102(e) date
 PRAI FR 1995-11094 19950921
 FR 1995-14492 19951207
 FR 1996-2265 19960223
 FR 1996-5082 19960423
 DT Utility
 FS Granted
 LN.CNT 991
 INCL INCLM: 424/451.000
 INCLS: 424/452.000; 424/457.000; 424/461.000; 424/462.000; 424/468.000;
 424/470.000; 424/474.000; 424/480.000; 424/482.000; 424/458.000;
 514/770.000; 514/784.000; 514/951.000; 514/960.000; 514/962.000;
 514/970.000
 NCL NCLM: 424/451.000
 NCLS: 424/452.000; 424/457.000; 424/458.000; 424/461.000; 424/462.000;
 424/468.000; 424/470.000; 424/474.000; 424/480.000; 424/482.000;
 514/770.000; 514/784.000; 514/951.000; 514/960.000; 514/962.000;
 514/970.000
 IC [7]
 ICM A61K009-22
 ICS A61K009-28; A61K009-52; A61K009-54; A61K009-56
 IPCI A61K0009-22 [ICM,7]; A61K0009-28 [ICS,7]; A61K0009-52 [ICS,7];
 A61K0009-54 [ICS,7]; A61K0009-56 [ICS,7]; A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-48 [I,A];
 A61K0009-48 [I,C*]; A61K0009-50 [I,A]; A61K0009-50 [I,C*];
 A61K0031-4164 [I,C*]; A61K0031-4184 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 EXF 424/468; 424/469; 424/470; 424/474; 424/480; 424/482; 424/451; 424/452;
 424/457; 424/458; 424/461; 424/462; 424/459; 424/475
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 50 OF 58 USPATFULL on STN

Full Text

AN 2000:141911 USPATFULL
 TI Oral pharmaceutical dosage form
 IN Depui, Helene, Goteborg, Sweden
 Rosinski, Adam, Molndal, Sweden
 PA Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)
 PI US 6136344 20001024
 WO 9624375 19960815
 AI US 1996-628712 19960415 (8)
 WO 1996-SE125 19960202
 19960415 PCT 371 date
 19960415 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1995-464775, filed on 7 Jun 1995,
 now abandoned
 PRAI SE 1995-422 19950206
 DT Utility
 FS Granted
 LN.CNT 1271

INCL INCLM: 424/470.000
 INCLS: 424/464.000; 424/468.000; 424/469.000
 NCL NCLM: 424/470.000
 NCLS: 424/464.000; 424/468.000; 424/469.000
 IC [7]
 ICM A61K009-26
 ICS A61K031-33
 IPCI A61K0009-26 [ICM,7]; A61K0031-33 [ICS,7]
 IPCR A61K0009-20 [I,A]; A61K0009-20 [I,C*]; A61K0009-28 [I,A];
 A61K0009-28 [I,C*]; A61K0009-50 [I,A]; A61K0009-50 [I,C*];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]
 EXF 424/451; 424/457; 424/458; 424/459; 424/462; 424/464; 424/468; 424/475;
 424/482; 424/469; 424/470; 514/300
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 51 OF 58 USPATFULL on STN

Full Text

AN 1998:127937 USPATFULL
 TI Effervescent composition and its production
 IN Shimizu, Toshihiro, Hyogo, Japan
 Tabata, Tetsuro, Osaka, Japan
 Kikuta, Junichi, Osaka, Japan
 PA Takeda Chemical Industries, Ltd, Osaka, Japan (non-U.S. corporation)
 PI US 5824339 19981020
 AI US 1996-708663 19960905 (8)
 PRAI JP 1995-257064 19950908
 DT Utility
 FS Granted
 LN.CNT 852
 INCL INCLM: 424/466.000
 INCLS: 424/465.000; 427/002.140; 427/002.210
 NCL NCLM: 424/466.000
 NCLS: 424/465.000; 427/002.140; 427/002.210
 IC [6]
 ICM A61K009-46
 IPCI A61K0009-46 [ICM,6]
 IPCR A61K0009-46 [I,C*]; A61K0009-46 [I,A]
 EXF 424/466; 424/465; 427/2.14; 427/2.21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 52 OF 58 USPATFULL on STN

Full Text

AN 1998:74829 USPATFULL
 TI Device for mixing a pharmaceutical composition with an other agent
 IN Glad, HÅkan Lars Christer, Åsa, Sweden
 Kers, Tore Anders, Sodertalje, Sweden
 Ruden, Mats Anders, Askim, Sweden
 PA Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)
 PI US 5772665 19980630
 AI US 1997-970235 19971114 (8)
 RLI Continuation of Ser. No. US 1995-360797, filed on 6 Jan 1995, now
 abandoned
 PRAI SE 1993-3630 19931103
 SE 1994-1010 19940325
 DT Utility
 FS Granted
 LN.CNT 580
 INCL INCLM: 604/082.000
 INCLS: 604/085.000; 604/187.000; 604/191.000; 604/213.000; 604/231.000;
 604/236.000; 604/089.000
 NCL NCLM: 604/082.000
 NCLS: 604/085.000; 604/089.000; 604/107.000; 604/191.000; 604/213.000;
 604/231.000; 604/236.000
 IC [6]
 ICM A61M037-00
 IPCI A61M0037-00 [ICM,6]
 IPCR A61M0005-178 [I,C*]; A61M0005-178 [I,A]; A61D0007-00 [I,C*];
 A61D0007-00 [I,A]; A61J0001-00 [N,C*]; A61J0001-00 [N,A];
 A61J0007-00 [I,C*]; A61J0007-00 [I,A]; A61M0003-00 [I,C*];
 A61M0003-00 [I,A]; A61M0005-28 [I,C*]; A61M0005-28 [I,A];
 A61M0005-31 [I,C*]; A61M0005-31 [I,A]; A61M0005-315 [I,C*];
 A61M0005-315 [I,A]

EXF 604/82; 604/85; 604/187; 604/191; 604/213; 604/231; 604/236; 604/89

L15 ANSWER 53 OF 58 USPAT2 on STN

Full Text

AN 2007:55439 USPAT2
TI Stable drug form for oral administration with benzimidazole derivatives
as active ingredient and process for the preparation thereof
IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 7276253 B2 20071002
AI US 2006-502830 20060811 (11)
RLI Division of Ser. No. US 2003-665081, filed on 16 Sep 2003, ABANDONED
Continuation of Ser. No. US 2001-947166, filed on 5 Sep 2001, Pat. No.
US 6623759 Continuation of Ser. No. US 1998-219985, filed on 23 Dec
1998, ABANDONED Continuation of Ser. No. WO 1997-EP3387, filed on 27 Jun
1997, PENDING
PRAI DE 1996-19626045 19960628
DT Utility
FS GRANTED
LN.CNT 994
INCL INCLM: 424/472.000
INCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000;
424/490.000; 424/494.000; 424/472.000
NCL NCLM: 424/472.000
NCLS: 424/464.000; 424/471.000; 424/474.000; 424/480.000; 424/489.000;
424/490.000; 424/494.000; 514/338.000
IC IPCI A61K0009-24 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]
IPCI-2 A61K0009-14 [I,A]; A61K0009-16 [I,A]; A61K0009-20 [I,A];
A61K0009-24 [I,A]; A61K0009-28 [I,A]
IPCR A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0009-16 [I,C];
A61K0009-16 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,A];
A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-28 [I,C];
A61K0009-28 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 54 OF 58 USPAT2 on STN

Full Text

AN 2003:288260 USPAT2
TI Stable oral pharmaceutical dosage forms
IN Chen, Jivn-Ren, Shreveport, LA, UNITED STATES
PA Sage Pharmaceuticals, Inc., Shreveport, LA, UNITED STATES (U.S.
corporation)
PI US 7041316 B2 20060509
AI US 2003-422338 20030424 (10)
RLI Division of Ser. No. US 1997-141476, Pat. No. US 6726927 A 371 of
International Ser. No. WO 1998-US9449, filed on 8 May 1998
Continuation-in-part of Ser. No. US 1997-950432, filed on 15 Oct 1997,
ABANDONED
PRAI US 1997-46089P 19970509 (60)
DT Utility
FS GRANTED
LN.CNT 635
INCL INCLM: 424/463.000
INCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
NCL NCLM: 424/463.000; 424/452.000
NCLS: 424/451.000; 424/456.000; 424/464.000; 424/474.000; 424/478.000;
424/480.000; 424/482.000; 424/489.000; 514/925.000; 514/962.000
IC IPCI A61K0009-48 [ICM, 7]
IPCI-2 A61L0009-48 [I,A]; A61L0009-64 [I,A]; A61L0009-20 [I,A];
A61L0009-18 [I,C*]; A61L0009-32 [I,A]; A61L0009-14 [I,A]
IPCR A61K0009-30 [I,C]; A61K0009-32 [I,A]; A61K0009-28 [I,C*];
A61K0009-28 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A];
A61K0009-52 [I,C]; A61K0009-64 [I,A]; A61K0031-4164 [I,C*];
A61K0031-4184 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61L0009-14 [I,C]; A61L0009-18 [I,C]; A61L0009-20 [I,A]
EXF 424/463; 424/451; 424/456; 424/464; 424/474; 424/478; 424/480; 424/482;

424/489; 514/925; 514/962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 55 OF 58 USPAT2 on STN

Full Text

AN 2003:187448 USPAT2
TI Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
IN Chen, Chih-Ming, Davie, FL, United States
Kositprapa, Unchalee, Davie, FL, United States
PA Andrx Labs LLC, Davie, FL, United States (U.S. corporation)
PI US 6869615 B2 20050322
AI US 2002-282820 20021028 (10)
RLI Continuation of Ser. No. US 2000-659222, filed on 11 Sep 2000, now patented, Pat. No. US 6544556
DT Utility
FS GRANTED
LN.CNT 1196
INCL INCL: 424/469.000
INCL: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000; 424/468.000; 424/489.000; 424/470.000; 424/474.000; 424/490.000
NCL NCLM: 424/469.000; 424/470.000
NCL: 424/451.000; 424/452.000; 424/457.000; 424/458.000; 424/465.000; 424/468.000; 424/470.000; 424/474.000; 424/489.000; 424/490.000
IC [7]
ICM A61K009-20
ICS A61K009-22; A61K009-26; A61K009-28; A61K009-54
IPCI A61K0009-26 [ICM, 7]
IPCI-2 A61K0009-20 [ICM, 7]; A61K0009-22 [ICS, 7]; A61K0009-26 [ICS, 7]; A61K0009-28 [ICS, 7]; A61K0009-54 [ICS, 7]; A61K0009-52 [ICS, 7, C*]
IPCR A61K0009-22 [I, C*]; A61K0009-22 [I, A]; A61K0009-24 [I, C*]; A61K0009-24 [I, A]; A61K0009-26 [I, C*]; A61K0009-26 [I, A]; A61K0009-28 [N, C*]; A61K0009-28 [N, A]; A61K0009-30 [I, C*]; A61K0009-30 [I, A]; A61K0009-32 [I, A]; A61K0009-34 [I, A]; A61K0009-36 [I, A]; A61K0009-48 [I, C*]; A61K0009-48 [I, A]; A61K0009-50 [N, C*]; A61K0009-50 [N, A]; A61K0009-52 [I, C*]; A61K0009-54 [I, A]; A61K0009-58 [I, A]; A61K0009-60 [I, A]; A61K0009-62 [I, A]; A61K0031-185 [I, C*]; A61K0031-196 [I, A]; A61K0031-415 [I, C*]; A61K0031-415 [I, A]; A61K0031-44 [I, C*]; A61K0031-44 [I, A]; A61K0031-4427 [I, C*]; A61K0031-4439 [I, A]; A61K0045-00 [I, C*]; A61K0045-00 [I, A]; A61K0047-10 [I, C*]; A61K0047-10 [I, A]; A61P0015-00 [I, C*]; A61P0015-00 [I, A]; A61P0019-00 [I, C*]; A61P0019-02 [I, A]; A61P0029-00 [I, C*]; A61P0029-00 [I, A]; A61P0043-00 [I, C*]; A61P0043-00 [I, A]
EXF 424/489; 424/490; 424/469; 424/451; 424/452; 424/457; 424/458; 424/464; 424/465; 424/470; 424/472; 424/468; 424/474; 424/484; 424/455; 424/456; 424/480; 424/481; 424/482; 424/493; 424/494; 424/495; 424/497; 424/496; 424/477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 56 OF 58 USPAT2 on STN

Full Text

AN 2002:279721 USPAT2
TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6613354 B2 20030902
AI US 2002-90882 20020304 (10)
RLI Continuation of Ser. No. US 1999-471958, filed on 23 Dec 1999, now patented, Pat. No. US 6365184 Continuation of Ser. No. US 793078, now abandoned
DT Utility
FS GRANTED
LN.CNT 1287
INCL INCL: 424/458.000
INCL: 424/451.000; 424/452.000; 424/457.000
NCL NCLM: 424/458.000; 424/452.000
NCL: 424/451.000; 424/452.000; 424/457.000; 424/465.000; 514/338.000
IC [7]
ICM A61K009-48

ICS A61K009-52; A61K009-54
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-48
 [ICS,7]; A61K0009-20 [ICS,7]
 IPCI-2 A61K0009-48 [ICM,7]; A61K0009-52 [ICS,7]; A61K0009-54 [ICS,7];
 A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-24 [I,C*];
 A61K0009-24 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
 A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0045-00 [I,C*];
 A61K0045-06 [I,A]
 EXF 424/468; 424/465; 424/474; 424/489; 424/490; 424/469; 424/464; 424/470;
 424/471; 424/493; 424/494; 424/458; 424/457; 424/452; 424/451; 424/459;
 424/461; 424/462
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 57 OF 58 USPAT2 on STN

Full Text

AN 2002:105711 USPAT2
 TI Stable drug form for oral administration with benzimidazole derivatives
 as active ingredient and process for the preparation thereof
 IN Heese, Gerd-Ulfert, Munich, GERMANY, FEDERAL REPUBLIC OF
 Junger, Herbert, Dachau, GERMANY, FEDERAL REPUBLIC OF
 Laicher, Arnim, Sauerlach, GERMANY, FEDERAL REPUBLIC OF
 Lorck, Claudio, Munich, GERMANY, FEDERAL REPUBLIC OF
 Profitlich, Thomas, Munich, GERMANY, FEDERAL REPUBLIC OF
 Weiss, Gerd, Munich, GERMANY, FEDERAL REPUBLIC OF
 PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
 PI US 6623759 B2 20030923
 AI US 2001-947166 20010905 (9)
 RLI Continuation of Ser. No. US 1998-219985, filed on 23 Dec 1998, now
 abandoned
 PRAI DE 1996-19626045 19960628
 DT Utility
 FS GRANTED
 LN.CNT 950
 INCL INCLM: 424/480.000
 INCLS: 424/472.000; 424/475.000; 424/482.000; 424/490.000; 424/494.000;
 424/497.000; 424/461.000; 424/462.000; 514/772.300; 514/781.000
 NCL NCLM: 424/480.000; 424/490.000
 NCLS: 424/461.000; 424/462.000; 424/472.000; 424/475.000; 424/482.000;
 424/490.000; 424/494.000; 424/497.000; 514/772.300; 514/781.000
 IC [7]
 ICM A61K009-24
 ICS A61K009-32; A61K009-36; A61K009-58; A61K009-62
 IPCI A61K0009-16 [ICM,7]; A61K0009-50 [ICS,7]
 IPCI-2 A61K0009-24 [ICM,7]; A61K0009-32 [ICS,7]; A61K0009-36 [ICS,7];
 A61K0009-30 [ICS,7,C*]; A61K0009-58 [ICS,7]; A61K0009-62 [ICS,7];
 A61K0009-52 [ICS,7,C*]
 IPCR A61K0009-30 [I,C*]; A61K0009-32 [I,A]; A61K0009-36 [I,A];
 A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
 A61K0009-58 [I,A]; A61K0009-62 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-4439 [I,A]
 EXF 424/461; 424/462; 424/494; 424/497; 424/459; 424/468; 424/476; 424/480;
 424/482; 424/490; 424/475
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 58 OF 58 USPAT2 on STN

Full Text

AN 2002:85601 USPAT2
 TI Substituted benzimidazole dosage forms and method of using same
 IN Phillips, Jeffrey O., Ashland, MO, United States
 PA Curators of the University of Missouri, Columbia, MO, United States
 (U.S. corporation)
 PI US 6645988 B2 20031111
 AI US 2001-901942 20010709 (9)
 RLI Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000,
 now patented, Pat. No. US 6489346 Continuation-in-part of Ser. No. US
 1998-183422, filed on 30 Oct 1998, now abandoned Continuation-in-part of
 Ser. No. US 1996-680376, filed on 15 Jul 1996, now patented, Pat. No. US
 5840737
 PRAI US 1996-9608P 19960104 (60)
 DT Utility

FS GRANTED
LN.CNT 4173
INCL INCLM: 514/338.000
INCLS: 546/273.700; 548/307.100; 514/395.000
NCL NCLM: 514/338.000
NCLS: 514/395.000; 546/273.700; 548/307.100
IC [7]
ICM A61K031-4439
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]
IPCI-2 A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-20 [I,C*];
A61K0009-20 [I,A]; A61K0009-24 [I,C*]; A61K0009-24 [I,A];
A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-46 [I,C*];
A61K0009-46 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A];
A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]; A61K0031-519 [I,C*]; A61K0031-522 [I,A];
A61K0033-00 [I,C*]; A61K0033-00 [I,A]; A61K0033-06 [I,C*];
A61K0033-06 [I,A]; A61K0036-00 [I,C*]; A61K0036-00 [I,A];
A61K0036-185 [I,C*]; A61K0036-534 [I,A]; A61K0036-82 [I,A];
A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-02 [I,C*];
A61K0047-02 [I,A]
EXF 514/338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d pi kwic 50-58

L15 ANSWER 50 OF 58 USPATFULL on STN

Full Text

PI US 6136344 20001024

WO 9624375 19960815

CLM What is claimed is:

. . . consisting essentially of, as a first component, at least one antibacterial compound, and as a second component, an acid susceptible **proton pump inhibitor**, wherein: (a) the composition is in the form of a multiple unit tablet; (b) the **proton pump inhibitor** is in the form of pellets covered with an enteric coating polymer **layer**; (c) the first component is separated from the **proton pump inhibitor** by the enteric coating **layer** covering the second component; and (d) the enteric coating **layer** has mechanical properties such that the acid resistance of the enteric coated pellets is not significantly affected by compression of. . .

4. The composition according to claim 1, wherein the antibacterial component in the form of **granules** of the antibacterial component.

5. The composition of claim 1, wherein the **proton pump inhibitor** is omeprazole or a pharmaceutically acceptable salt of omeprazole.

6. The composition of claim 1, wherein the **proton pump inhibitor** is omeprazole, an alkaline salt of omeprazole, a (-)-enantiomer of omeprazole or an alkaline salt of the (-)-enantiomer of omeprazole.

7. The composition of claim 1, wherein the **proton pump inhibitor** is S-omeprazole magnesium salt.

8. The composition of claim 1, wherein the **proton pump inhibitor** is **lansoprazole**, a pharmaceutically acceptable salt of **lansoprazole**, a single enantiomer of **lansoprazole** or a pharmaceutically acceptable salt of the enantiomer of **lansoprazole**.

11. The composition of claim 1, wherein the amount of the antibacterial component is in the range of 100-900 mg and the amount of the **proton pump inhibitor** is in the range of 10-80 mg.

. . . wherein the amount of the first antibacterial component is in the range of 250-650 mg and the amount of the **proton pump inhibitor** is in the range of 20-40 mg.

13. The composition of claim 1, wherein the tablet is in the form of two separate **layers**.

14. The composition of claim 13, wherein the acid susceptible **proton**

pump inhibitor is located in one **layer** and wherein the antibacterial component is located in the other **layer**.

15. The composition of claim 1, wherein the acid resistance of the enteric coating **layered** pellets is in compliance with the requirements on enteric coating **layered** articles as defined in the United States Pharmacopeia and does not decrease more than 10% upon tableting of the pellets. . . .

16. The composition of claim 1, wherein the **proton pump inhibitor** is covered by a separating **layer** located underneath the enteric coating **layer**.

17. The composition of claim 1, wherein the enteric coating **layer** of the pellet comprises more than one **layer**.

18. The composition of claim 1, wherein the enteric coating **layer** of the pellet comprises a plasticized enteric coating **layer** material.

19. The composition of claim 1, wherein the enteric coating **layered** pellets are further covered with an over-coating **layer** comprising a pharmaceutically acceptable excipient.

22. The composition of claim 20, wherein the tablet is dispersible to a suspension of individually enteric coating **layered** pellets in an aqueous liquid.

23. The composition of claim 18, wherein the amount of plasticizer is 20-50% by weight of the enteric coating **layer** polymer.

. . . consisting essentially of, as a first component, at least one antibacterial compound, and as a second component, an acid susceptible **proton pump inhibitor**, wherein the process comprises the steps of: (a) preparing the **proton pump inhibitor** in the form of enteric coating **layered** pellets; (b) mixing the enteric coated pellets with a prepared **granules** of the antibacterial component; (c) drying the mixture; and (d) compressing the mixture into a multiple unit tablet without affecting any significant change of the acid resistance of the enteric coating **layered** pellets.

L15 ANSWER 51 OF 58 USPTAFULL on STN

Full Text

PI US 5824339 19981020

CLM What is claimed is:

1. An effervescent composition which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of an acid-sensitive physiologically active substance and an enteric coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm ; (b) an effervescing component; and. . . .

2. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is physiologically inactive.

3. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is spherical.

7. The effervescent composition as claimed in claim 6, wherein said benzimidazole derivative is **lansoprazole**.

8. The effervescent composition as claimed in claim 1, wherein the proportion of said enteric coating **layer** is about 35 to about 50% by weight of the core-shell powder.

. . . The effervescent composition as claimed in claim 1, which comprises (a) a core-shell powder which comprises a physiologically inactive fine **granular** core coated with a **layer** comprising a water-soluble cellulose derivative and an effective amount of **lansoprazole** and an enteric coating **layer**; (b) an effervescing component selected from alkali metal carbonates; and (c) an auxiliary effervescing agent selected from edible hydroxy-carboxylic acids;. . . .

13. A method of producing an effervescing composition which comprises

mixing (a) a core-shell powder which comprises a fine **granular** core having specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm ; with (b) an effervescing component; . .

. . . suspension of an acid-sensitive physiologically active substance for oral administration which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder to not exceeding about 300 μm ; (b) an effervescing component; and. . .

L15 ANSWER 52 OF 58 USPATFULL on STN

Full Text

PI US 5772665 19980630

CLM What is claimed is:

11. A syringe according to claim 10, wherein said at least one moisture barrier is comprised by an aluminium **layer**.

12. A syringe according to any of claims 1-2, wherein said pharmaceutical composition is constituted by enteric coated pellets of a **proton pump inhibitor** such as omeprazole pellets mixed with a dry gelforming agent.

13. A process for preparing a pharmaceutical preparation by mixing a pharmaceutical, preferably dry and **granular**, composition with a, preferably fluid, agent shortly before the administration thereof to a living being, comprising the following steps: filling. . .

14. A method for oral administration of a pharmaceutical preparation, which is achieved by mixing a preferably dry and **granular**, composition with a preferably fluid agent, said composition being contained in the chamber of the syringe according to claims 1. . .

L15 ANSWER 53 OF 58 USPAT2 on STN

Full Text

PI US 7276253 B2 20071002

CLM What is claimed is:

. . . for oral administration which comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with pharmaceutical adjuvants; (b) an intermediate **layer** applied onto the core; and (c) a gastric juice-resistant outer **layer**, wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity.

. . . according to claim 1, wherein the core is present in the form of pellet cores, tablets, microtablets, or as a **granulate**.

7. The method according to claim 1, wherein the polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 7.0.

8. The method according to claim 7, wherein the polymeric **layered** material is selected from the group consisting of a partially neutralized copolymer of methacrylic acid and ethylacrylate, a copolymer of. . .

9. The method according to claim 1, wherein the intermediate **layer** further comprises a plasticizer.

11. The method according to claim 1, wherein the intermediate **layer** forms a gel **layer** with penetration of protons through the outer **layer**.

12. The method according to claim 1, wherein the intermediate **layer** possesses a thickness of from about 5 to about 30 μm .

13. The method according to any one of claims 1 to 12, wherein the gastric juice-resistant outer **layer** in (c) contains a copolymer selected from the group consisting of copolymers of methacrylic acid and

ethylacrylate, copolymers of methacrylic. . .

14. The method according to claim 13, wherein the gastric juice-resistant outer **layer** contains compounds selected from the group consisting of pharmaceutically acceptable antitacking agents, dispersion agents, pigments and colorants.

16. The method according to claim 1, wherein the gastric juice-resistant outer **layer** has a **layer** of thickness from about 20 to about 60 μm .

- . . . medicament for oral administration comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with mannite and hydroxypropylcellulose as adjuvants without alkaline additives; (b) a reactive intermediate **layer** applied on the core with a thickness from about 5 to about 30 μm of a copolymer of methacrylic acid. . . neutralized with sodium hydroxide to a pH range of about 5.5 to about 7.0; and (c) a gastric juice-resistant outer **layer** of a copolymer of methacrylic acid and ethylacrylate with a thickness from about 30 to about 60 μm .

18. The method according to claim 1, wherein the intermediate **layer** is formed as a plurality of single **layers**.

19. The method according to claim 1, wherein the gastric juice-resistant outer **layer** is formed as a plurality of single **layers**.

20. The method according to claim 1, wherein the pH transition at the border of the gastric juice-resistant outer **layer** to the reactive intermediate **layer** is formed as a gradient.

- . . . the Diclofenac is present as a formulation which comprises: (a) a Diclofenac-containing core together with adjuvants; (b) a reactive intermediate **layer** of gastric juice-resistant polymeric **layered** material partially neutralized with alkali; and (c) a gastric juice-resistant outer **layer**.

L15 ANSWER 54 OF 58 USPAT2 on STN

Full Text

PI US 7041316 B2 20060509

CLM What is claimed is:

- . . . A pharmaceutical dosage form for oral administration to human being or animal host which consists essentially of: (a) a core **granulation** formed by dry mixing, without using an aqueous **granulation** solution, an acid-unstable drug with an alkaline substance and a pharmaceutical excipient or excipients, wherein the core **granulation** is capable of being quantitatively filled into an empty hard gelatin capsule shell having an outer surface and an inner surface, wherein the hard gelatine capsule shell separates the core **granulation** from an enteric coating, and wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, **lansoprazole**, or a pharmaceutical salt of **lansoprazole**; and (b) the enteric coating being disposed on the outer surface of the hard gelatin capsule shell to prevent the. . .
- . . . shell separates the core tablet from an enteric coating, and wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, **lansoprazole**, or a pharmaceutical salt of **lansoprazole**; and (b) the enteric coating being disposed on the outer surface of the hard gelatin capsule shell to protect the. . .
- . . . and then by direct compression, wherein the acid-unstable drug is omeprazole, sodium omeprazole, potassium omeprazole, or a pharmaceutical salt of **lansoprazole**, and wherein the core tablet is subcoated with a protective **layer** as a barrier to: (i) separate the acid-unstable active drug in the core tablet from an enteric coating; and (ii). . .
- . . . is selected from one or any combination of the group consisting of alkaline metallic salt of carbonic acid, calcium carbonate, **granulated** calcium carbonate, dicalcium phosphate anhydrous, dibasic sodium phosphate anhydrous, tricalcium phosphate anhydrous, sodium carboxymethylcellulose, calcium carboxymethylcellulose, magnesium aluminum silicate, sodium. . .

7. The pharmaceutical dosage form according to claim 3 wherein the protective **layer** comprises: (a) non-ionic protective polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl

cellulose, and hydroxypropyl cellulose polyvinylpyrrolidone; (b). . .
. . . (a) a core formulation comprising an acid-unstable drug and an
alkaline substance, formed by dry mixing without using an aqueous
granulating solution, wherein the acid-unstable drug is omeprazole,
sodium omeprazole, potassium omeprazole, **lansoprazole**, or a
pharmaceutical salt of **lansoprazole**; (b) a hard gelatin capsule shell
housing the core formulation, wherein the gelatin capsule shell has an
outer surface and. . .

11. The oral pharmaceutical preparation of claim 8, wherein the core
formulation is in the form of powder or **granules**.

13. The pharmaceutical dosage form according to claim 8 wherein the
alkaline substance is selected from one or any combination of the group
consisting of alkaline metallic salt of carbonic acid, calcium
carbonate, **granulated** calcium carbonate, dicalcium phosphate
anhydrous, dibasic sodium phosphate anhydrous, tricalcium phosphate
anhydrous, sodium carboxymethylcellulose, calcium
carboxymethylcellulose, magnesium aluminum silicate, sodium. . .

L15 ANSWER 55 OF 58 USPAT2 on STN

Full Text

PI US 6869615 B2 20050322

CLM What is claimed is:

1. A solid oral dosage form comprising a) a population of substrates
comprising a **proton-pump inhibitor**; b) an enteric coating **layer**
coated over said substrates; and c) an NSAID coating **layer** coated over
said enteric coated substrates.

4. The solid dosage form of claim 1 wherein said **proton pump
inhibitor** is selected from the group consisting of omeprazole,
lansoprazole, rabeprazole, **pantoprazole**, **laminoprazole**, single
enantiomers thereof, alkaline salts thereof and mixtures thereof.

5. The solid dosage form of claim 1 wherein said **proton pump
inhibitor** is omeprazole or a pharmaceutically acceptable salt thereof.

6. The solid dosage form of claim 1 wherein said substrates are a
plurality of inert beads and said **proton-pump inhibitor** is coated
onto said beads.

8. The solid dosage form of claim 7 wherein said **proton pump
inhibitor** is selected from the group consisting of omeprazole,
lansoprazole, rabeprazole, **pantoprazole**, **laminoprazole**, single
enantiomers thereof, alkaline salts thereof and mixtures thereof.

9. The solid dosage form of claim 8 wherein said **proton pump
inhibitor** is omeprazole or a pharmaceutically acceptable salt thereof.

10. A solid dosage form for oral administration comprising a compressed
matrix comprising an NSAID and a **proton-pump inhibitor**, and a
retardant material in an effective amount to provide a controlled
release of said NSAID and said **proton-pump inhibitor** sufficient to
provide a therapeutic effect for at least about 24 hours; and said
compressed matrix overcoated with a material suitable to prevent contact
of said **proton pump inhibitor** with acidic gastric juice after oral
administration.

11. The solid dosage form of claim 10 wherein said **proton pump
inhibitor** is selected from the group consisting of omeprazole,
lansoprazole, rabeprazole, **pantoprazole**, **laminoprazole**, single
enantiomers thereof, alkaline salts thereof and mixtures thereof.

12. The solid dosage form of claim 11 wherein said **proton pump
inhibitor** is omeprazole or an alkaline salt thereof.

13. The solid dosage form of claim 10, wherein said **proton pump
inhibitor** is in an amount effective to inhibit gastrointestinal side
effects associated with oral administration of said NSAID or
pharmaceutically acceptable. . .

14. The solid dosage form of claim 10 wherein said material suitable to
prevent contact of said **proton pump inhibitor** with acidic gastric
juice is an enteric coating.

18. The solid dosage form of claim 10 wherein said NSAID, said **proton-pump inhibitor** and said retardant material are in **granular** form prior to compression.

. . . material in an effective amount to provide a controlled release of said NSAID; and a plurality of particles comprising a **proton pump inhibitor** coated onto the surface of a plurality of inert beads and overcoated with a material suitable to prevent contact of said **proton pump inhibitor** with acidic gastric juice after oral administration; said dosage form containing a sufficient amount of said particles to provide an effective dose of said **proton pump inhibitor** to inhibit gastrointestinal side effects associated with oral administration of said NSAID; said compressed matrix and said dose of **proton pump inhibitor** contained within a capsule.

21. The oral solid dosage form of claim 20, wherein said **proton-pump inhibitor** is selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, **pantoprazole**, **leminoprazole**, single enantiomers thereof, alkaline salts thereof and mixtures thereof.

22. The solid oral dosage form of claim 1, wherein the **proton-pump inhibitor** is in a therapeutically effective amount.

23. The solid oral dosage form of claim 1, wherein the **proton-pump inhibitor** is in an amount effective to inhibit gastrointestinal side effects associated with oral administration of said diclofenac or pharmaceutically acceptable. . .

L15 ANSWER 56 OF 58 USPAT2 on STN

Full Text

PI US 6613354 B2 20030902

CLM What is claimed is:

1. A capsule formulation comprising an acid susceptible **proton pump inhibitor**, one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), an enteric coating **layer** to protect the **proton pump inhibitor** and, optionally, pharmaceutically acceptable excipients.

2. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer**.

3. The capsule formulation according to claim 1, further comprising a separating **layer** located underneath the enteric coating **layer**.

4. The capsule formulation according to claim 1, wherein the dosage form comprises the **proton pump inhibitor** and one NSAID.

5. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is omeprazole, an alkaline salt of omeprazole, a single enantiomer of omeprazole or an alkaline salt of the single enantiomer.

. . .
6. The capsule formulation according to claim 5, wherein the **proton pump inhibitor** is S-omeprazole magnesium salt.

7. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is **lansoprazole**, a pharmaceutically acceptable salt of **lansoprazole**, a single enantiomer of **lansoprazole** or a pharmaceutically acceptable salt of the single enantiomer.

8. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is **pantoprazole**, a pharmaceutically acceptable salt of **pantoprazole**, a single enantiomer of **pantoprazole** or a pharmaceutically acceptable salt of the single enantiomer.

11. The capsule formulation according to claim 1, wherein the amount of the **proton pump inhibitor** is in the range of 10-80 mg and the amount of NSAID(s) is in the range of 10-800 mg.

12. The capsule formulation according to claim 1, wherein the amount of the **proton pump inhibitor** is in the range of 10-40 mg and the amount of NSAID(s) is in the range of 10-500 mg.

13. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating **layered** pellets is in compliance with the requirements on enteric coating **layered** articles defined in the United States Pharmacopeia.

14. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating **layered** pellets does not decrease more than 10% in compliance with the requirements on enteric coating **layered** articles defined in the United States Pharmacopeia.

16. The capsule formulation according to claim 2, wherein the enteric coating **layered** pellets are further covered with an over-coating **layer** comprising pharmaceutically acceptable excipients.

17. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer**, and wherein the NSAID(s), is in the form of pellets covered with an enteric coating **layer**.

18. The capsule formulation according to claim 1, wherein the **proton pump inhibitor** is in the form of pellets covered with an enteric coating **layer**, and wherein the NSAID(s) is in the form of pellets coating **layered** with an extended release film.

19. A process for the manufacture of a capsule formulation comprising a **proton pump inhibitor** and one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), wherein the process comprises the steps: (a) preparing the **proton pump inhibitor** in the form of enteric coating **layered** pellets, and (b) filling a capsule with the pellets, the NSAID(s) selected from the group consisting of prepared NSAID **granules**, enteric coating **layered** NSAID pellets, and NSAID pellets coating **layered** with an extended release film, and optionally, pharmaceutically acceptable excipients.

L15 ANSWER 57 OF 58 USPAT2 on STN

Full Text

PI US 6623759 B2 20030923

CLM What is claimed is:

- . . . for oral administration which comprises: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with pharmaceutical adjuvants; (b) an intermediate **layer** applied onto the core; and (c) a gastric juice-resistant outer **layer**, wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity.
- . . . according to claim 1, wherein the core is present in the form of pellet cores, tablets, microtablets, or as a **granulate**.

7. The medicament according to claim 1, wherein the polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 7.0.

8. The medicament according to claim 7, wherein the polymeric **layered** material is selected from the group consisting of a partially neutralized copolymer of methacrylic acid and ethylacrylate, a copolymer of. . .

9. The medicament according to claim 1, wherein the intermediate **layer** further comprises a plasticizer.

11. The medicament according to claim 1, wherein the intermediate **layer** forms a gel **layer** with penetration of protons through the outer **layer**.

12. The medicament according to claim 1, wherein the intermediate **layer** possesses a thickness of from about 5 to about 30 μm .

13. The medicament according to any one of claims 1 to 12, wherein the gastric juice-resistant outer **layer** in (c) contains a copolymer selected from the group consisting of copolymers of methacrylic acid and ethylacrylate, copolymers of methacrylic. . .

14. The medicament according to claim 13, wherein the gastric

juice-resistant outer **layer** contains compounds selected from the group consisting of pharmaceutically acceptable antitackling agents, dispersion agents, pigments, and colorants.

16. The medicament according to claim 1, wherein the gastric juice-resistant outer **layer** has a **layer** of thickness from about 20 to about 60 μm .

- . . . according to claim 1 comprising: (a) a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with mannite and hydroxypropylcellulose as adjuvants without alkaline additives; (b) a reactive intermediate **layer** applied on the core with a thickness from about 5 to about 30 μm of a copolymer of methacrylic acid. . . . neutralized with sodium hydroxide to a pH range of about 5.5 to about 7.0; and (c) a gastric juice-resistant outer **layer** of a copolymer of methacrylic acid and ethylacrylate with a thickness from about 30 to about 60 μm .

18. The medicament according to claim 1, wherein the intermediate **layer** is formed as a plurality of single **layers**.

19. The medicament according to claim 1, wherein the gastric juice-resistant outer **layer** is formed as a plurality of single **layers**.

20. The medicament according to claim 1, wherein the pH transition at the border of the gastric juice-resistant outer **layer** to the reactive intermediate **layer** is formed as a gradient.

- . . . (a) forming a molded article as a core which contains an active ingredient selected from the group consisting of Omeprazole, **Lansoprazole**, and **Pantoprazole**, together with pharmaceutical adjuvants; (b) applying an intermediate **layer** onto the molded article; and (c) applying onto the intermediate **layer** a gastric juice-resistant **layer**, wherein the intermediate **layer** is a reactive **layer** comprising a gastric juice-resistant polymeric **layered** material partially neutralized with alkali and having cation exchange capacity.
- 22. The method according to claim 21, wherein the gastric juice-resistant polymeric **layered** material is partially neutralized with alkali to a pH range of from about 5.5 to about 7.0 before spraying.
- . . . the Diclofenac is present as a formulation which comprises: (a) a Diclofenac-containing core together with adjuvants; (b) a reactive intermediate **layer** of gastric juice-resistant polymeric **layered** material partially neutralized with alkali; and (c) a gastric juice-resistant outer **layer**.

29. The medicament according to claim 7, wherein the gastric juice-resistant polymeric **layered** material is partially neutralized to a pH range of about 5.5 to about 6.5

30. The medicament according to claim 16, wherein the gastric juice-resistant outer **layer** has a **layer** thickness of from about 30 to 60 μm .

L15 ANSWER 58 OF 58 USPAT2 on STN

Full Text

PI US 6645988 B2 20031111

CLM What is claimed is:

- . . . A solid oral pharmaceutical dosage form that is not enteric-coated, comprising: active ingredients consisting essentially of: (a) at least one **proton pump inhibitor** (PPI) selected from the group consisting of omeprazole, **lansoprazole**, **rabeprazole**, **esomeprazole**, **pantoprazole**, **pariprazole**, and **leminoprazole**, and an enantiomer, isomer, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg;. . . one optional Secondary Essential Buffer in a total amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor**; and a pharmaceutically-acceptable excipient; wherein the dosage form is selected from the group consisting of a suspension tablet, chewable tablet,. . . .

2. The dosage form of claim 1, wherein the **proton pump inhibitor** is in an amount from approximately 10 mg to approximately 100 mg.
3. The dosage form of claim 1, wherein the **proton pump inhibitor** is omeprazole.
4. The dosage form of claim 1, wherein the **proton pump inhibitor** is **lansoprazole**.
5. The dosage form of claim 1, wherein the **proton pump inhibitor** is **pantoprazole**.
6. The dosage form of claim 1, wherein the **proton pump inhibitor** is rabeprazole.
7. The dosage form of claim 1, wherein the **proton pump inhibitor** is esomeprazole.
8. The dosage form of claim 1, wherein the **proton pump inhibitor** is **pariprazole**.
9. The dosage form of claim 1, wherein the **proton pump inhibitor** is **leminoprazole**.

24. A solid oral pharmaceutical dosage form that is not enteric-coated, comprising: an outer **layer** and an inner core; the outer **layer** comprising active ingredients consisting essentially of at least one Primary Essential Buffer; and the inner core comprising active ingredients consisting essentially of at least one **proton pump inhibitor** selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, esomeprazole, **pantoprazole**, **pariprazole**, and **leminoprazole**, or an enantiomer, isomer, free base, or salt thereof, and at least one buffering agent selected from the group consisting of a Primary Essential Buffer and a Secondary Essential Buffer; wherein the total amount of the **proton pump inhibitor** is approximately 5 mg to approximately 300 mg; and the total amount of the buffering agent is approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor**.

- . . . effective to elevate pH of gastric fluid of the subject upon oral administration to at least 3.7 from time the **proton pump inhibitor** comes in contact with the gastric fluid throughout dwell time in the stomach.

29. A non-enteric coated solid oral pharmaceutical dosage form, comprising: (a) active ingredients consisting essentially of: (i) a **proton pump inhibitor** (PPI) selected from the group consisting of omeprazole, **lansoprazole**, rabeprazole, esomeprazole, **pantoprazole**, **pariprazole**, and **leminoprazole**, and an enantiomer, isomer, free base, and salt thereof, in an amount of approximately 5 mg to approximately 300 mg; . . . one optional Secondary Essential Buffer in a total amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of **proton pump inhibitor**; and (b) a pharmaceutically-acceptable excipient; wherein the dosage form is created by a method comprising: i) blending the **proton pump inhibitor**, the Primary Essential Buffer, the optional Secondary Essential Buffer, and the pharmaceutically-acceptable excipient; and ii) formulating the **proton pump inhibitor**, the Primary Essential Buffer, the optional Secondary Essential Buffer, and the pharmaceutically-acceptable excipient into a powder, tablet, suspension tablet, chewable tablet, capsule, two-part tablet, two-part capsule, effervescent powder, pellet, **granule** or effervescent tablet.

=> d pi kwic 46 48 51

L15 ANSWER 46 OF 58 USPATFULL on STN

Full Text

PI US 6328994 B1 20011211

WO 9959544 19991125

CLM What is claimed is:

1. An orally disintegrable tablet which comprises (i) fine **granules** having an average particle diameter of 400 μm or less, which fine **granules** comprise a composition coated by an enteric coating **layer** comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having 10 weight % or more of an acid-labile physiologically active substrate that is **lansoprazole** and (ii) an additive wherein said tablet having a hardness strength of about 1 to about 20 kg, is orally.
2. An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine **granule** is 300 to 400 μm .
3. An orally disintegrable tablet of claim 1, wherein the fine **granules** further comprise a basic inorganic salt.
5. An orally disintegrable tablet of claim 1, wherein the composition coated by an enteric coating **layer** is further coated by a coating **layer** which comprises a water-soluble sugar alcohol.
7. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine **granules** is practically 425 μm or less.
8. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine **granules** is practically 400 μm or less.
15. An orally disintegrable tablet of claim 1, wherein the fine **granules** are produced by fluidized-bed **granulation** method.
16. An orally disintegrable tablet of claim 1, wherein the enteric coating **layer** comprises an aqueous enteric polymer agent.
 - . . . of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine **granules**.
 - . . . an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine **granule**.
29. Fine **granules** having an average particle diameter of 400 μm or less, which comprise a composition coated by an enteric coating **layer** comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having (i) 25 weight % or more of an acid-labile physiologically active substance that is **lansoprazole** and (ii) a basic inorganic salt.
30. Fine **granules** of claim 28, wherein the average particle diameter of the fine **granules** is 300 to 400 μm .
31. Fine **granules** of claim 28, wherein the particle diameter of the fine **granules** is practically 425 μm or less.
32. Fine **granules** of claim 28, wherein the particle diameter of the fine **granules** is practically 400 μm or less.
33. Fine **granules** of claim 28, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.
34. Fine **granules** of claim 28, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, . . .
35. Fine **granules** of claim 34, wherein the core comprises 50 weight % or more of lactose.
36. Fine **granules** of claim 28, wherein the composition comprises 25 to 40 weight % of an acid-labile physiologically active substance.
37. Fine **granules** of claim 28, which are produced by fluidized-bed **granulation** method.
38. Fine **granules** of claim 28, wherein the enteric coating **layer** comprises an aqueous enteric polymer agent.
39. Fine **granules** of claim 38, wherein the aqueous enteric polymer

agent is a methacrylate copolymer.

40. Fine **granules** of claim 28, wherein the sustained-release agent is a methacrylate copolymer.

41. Fine **granules** of claim 28, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100. . .

42. Fine **granules** of claim 28, wherein the enteric coating **layer** is in an amount of 50 to 70 weight % relative to 100 weight % of the fine **granules**.

43. A tablet, **granule**, fine **granule**, capsule, effervescent or suspension preparation which comprises the fine **granules** of claim 28.

45. Fine **granules** of claim 38, wherein the sustained-release agent is in an amount of 5 to 30% relative to 100 weight %. . .

L15 ANSWER 48 OF 58 USPTAFULL on STN

Full Text

PI US 6228400 B1 20010508

CLM What is claimed is:

1. An orally administered pharmaceutical **granule** comprising: an inert core comprising at least one compound and/or mixture selected from the group consisting of starch, a mixture. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, a basic amino acid, and water; a protective coating deposited on said drug emulsion, wherein said protective. . .

2. The orally administered pharmaceutical **granule** according to claim 1, wherein said drug emulsion contains 30-60 wt % of water, 1-10 wt % of the non-ionic. . .

3. The orally administered pharmaceutical **granule** according to claim 1, wherein said basic amino acid is selected from the group consisting of arginine, lysine, histidine, and. . .

4. The orally administered pharmaceutical **granule** according to claim 1, wherein said non-ionic surfactant is polyoxypropylene-polyoxyethylene copolymers or polysorbates.

5. The orally administered pharmaceutical **granule** according to claim 1, wherein said polymer and said plasticizer in said enteric **layer** are at a weight ratio of no less than 10:1.

6. The orally administered pharmaceutical **granule** according to claim 1, wherein said **granule** is further encapsulated.

7. The orally administered pharmaceutical **granule** according to claim 1, wherein said **granule** is compressed into tablet by mixing with at least an excipient which is selected from the group consisting of lactose,. . .

8. A process of making an orally administered pharmaceutical **granule** according to claim 1 comprising: obtaining an inert core; coating the inert core with a drug emulsion which comprises a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, arginine, and water by spraying said drug emulsion onto said inert core; coating the drug emulsion with. . .

. . . and gastritis comprising orally administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical **granule** comprising: an inert core consisting essentially of at least one compound and/or mixture selected from the group consisting of starch,. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, a basic amino acid, and water; a protective coating deposited on said drug emulsion, wherein said protective. . .

10. An orally administered pharmaceutical **granule** comprising: an inert core comprising at least one compound and/or mixture selected from the group consisting of starch, a mixture. . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a protective coating. . .

11. The orally administered pharmaceutical **granule** according to claim

10, wherein said non-ionic surfactant is polyoxypropylene-polyoxyethylene copolymers or polysorbates.

12. The orally administered pharmaceutical **granule** according to claim 10, wherein said excipient is polyethylene glycol 6000 having a molecular weight between 7000 and 9000.

13. The orally administered pharmaceutical **granule** according to claim 10, wherein said polymer and said plasticizer in said enteric **layer** are at a weight ratio of no less than 10:1.

14. The orally administered pharmaceutical **granule** according to claim 10, wherein said protective coating further comprises a basic amino acid selected from the group consisting of. . .

15. The orally administered pharmaceutical **granule** according to claim 11, wherein said protective coating comprises one or more sublayers.

16. The orally administered pharmaceutical **granule** according to claim 15, wherein at least one of the sublayers contains a basic amino acid selected from the group. . .

17. The orally administered pharmaceutical **granule** according to claim 15, wherein none of the sublayers of the protective coating contains an alkaline salt or compound.

18. The orally administered pharmaceutical **granule** according to claim 10, wherein said **granule** is further encapsulated.

19. The orally administered pharmaceutical **granule** according to claim 10, wherein said **granule** is compressed into tablet by mixing with at least one said excipient which is selected from the group consisting of. . .

20. A process of making an orally administered pharmaceutical **granule** according to claim 10 comprising: obtaining an inert core; coating the inert core with a drug emulsion which comprises a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, arginine, and water by spraying said drug emulsion onto said inert core; coating the drug emulsion with. . .

. . . and gastritis comprising orally administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical **granule** comprising: an inert core consisting essentially of at least one compound and/or mixture selected from the group consisting of starch, . . . said inert core, wherein said drug emulsion comprises an effective amount of a free base omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a protective coating. . .

22. An orally administered pharmaceutical **granule** comprising: an inert core selected from the groups of compounds and/or mixtures consisting essentially of starch, a mixture of sugar. . . on said inert core, wherein said drug emulsion comprises an effective amount of a freebase omeprazole or a free base **lansoprazole**, a non-ionic surfactant, and water, wherein said drug emulsion does not contain an alkaline salt or compound; a first protective. . .

23. The orally administered pharmaceutical **granule** according to claim 22, wherein said second protective coating further comprises a basic amino acid which is selected from the. . .

L15 ANSWER 51 OF 58 USPATFULL on STN

Full Text

PI US 5824339 19981020

CLM What is claimed is:

1. An effervescent composition which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of an acid-sensitive physiologically active substance and an enteric coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm ; (b) an effervescing component; and. . .

2. The effervescent composition as claimed in claim 1, wherein said fine **granular** core is physiologically inactive.

3. The effervescent composition as claimed in claim 1, wherein said fine

granular core is spherical.

7. The effervescent composition as claimed in claim 6, wherein said benzimidazole derivative is **lansoprazole**.

8. The effervescent composition as claimed in claim 1, wherein the proportion of said enteric coating **layer** is about 35 to about 50% by weight of the core-shell powder.

- . . . The effervescent composition as claimed in claim 1, which comprises (a) a core-shell powder which comprises a physiologically inactive fine **granular** core coated with a **layer** comprising a water-soluble cellulose derivative and an effective amount of **lansoprazole** and an enteric coating **layer**; (b) an effervescing component selected from alkali metal carbonates; and (c) an auxiliary effervescing agent selected from edible hydroxy-carboxylic acids;. . .

13. A method of producing an effervescing composition which comprises mixing (a) a core-shell powder which comprises a fine **granular** core having specific volume not exceeding about 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder do not exceed about 300 μm ; with (b) an effervescing component;. . .

- . . . suspension of an acid-sensitive physiologically active substance for oral administration which comprises (a) a core-shell powder which comprises a fine **granular** core having a specific volume not exceeding 5 ml/g coated with a **layer** comprising a water-soluble polymer and an effective amount of acid-sensitive physiologically active substance and an enteric-coating **layer**, wherein the average particle diameters of the core-shell powder to not exceeding about 300 μm ; (b) an effervescing component; and. . .

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

129.90

130.11

STN INTERNATIONAL LOGOFF AT 19:12:06 ON 02 MAR 2008